<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35787292</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2047-9158</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>04</Day></PubDate></JournalIssue><Title>Translational neurodegeneration</Title><ISOAbbreviation>Transl Neurodegener</ISOAbbreviation></Journal><ArticleTitle>The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders.</ArticleTitle><Pagination><StartPage>36</StartPage><MedlinePgn>36</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">36</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40035-022-00308-y</ELocationID><Abstract><AbstractText>Neurological disorders (NDs) are characterized by progressive neuronal dysfunction leading to synaptic failure, cognitive impairment, and motor injury. Among these diseases, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) have raised a significant research interest. These disorders present common neuropathological signs, including neuronal dysfunction, protein accumulation, oxidative damage, and mitochondrial abnormalities. In this context, mitochondrial impairment is characterized by a deficiency in ATP production, excessive production of reactive oxygen species, calcium dysregulation, mitochondrial transport failure, and mitochondrial dynamics deficiencies. These defects in mitochondrial health could compromise the synaptic process, leading to early cognitive dysfunction observed in these NDs. Interestingly, skin fibroblasts from AD, PD, HD, and ALS patients have been suggested as a useful strategy to investigate and detect early mitochondrial abnormalities in these NDs. In this context, fibroblasts are considered a viable model for studying neurodegenerative changes due to their metabolic and biochemical relationships with neurons. Also, studies of our group and others have shown impairment of mitochondrial bioenergetics in fibroblasts from patients diagnosed with sporadic and genetic forms of AD, PD, HD, and ALS. Interestingly, these mitochondrial abnormalities have been observed in the brain tissues of patients suffering from the same pathologies. Therefore, fibroblasts represent a novel strategy to study the genesis and progression of mitochondrial dysfunction in AD, PD, HD, and ALS. This review discusses recent evidence that proposes fibroblasts as a potential target to study mitochondrial bioenergetics impairment in neurological disorders and consequently to search for new biomarkers of neurodegeneration.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Olesen</LastName><ForeName>Margrethe A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Laboratory of Neurodegenerative Diseases, Facultad de Ciencias de La Salud, Instituto de Ciencias Biom&#xe9;dicas, Universidad Aut&#xf3;noma de Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Villavicencio-Tejo</LastName><ForeName>Francisca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratory of Neurodegenerative Diseases, Facultad de Ciencias de La Salud, Instituto de Ciencias Biom&#xe9;dicas, Universidad Aut&#xf3;noma de Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintanilla</LastName><ForeName>Rodrigo A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0002-9582-6379</Identifier><AffiliationInfo><Affiliation>Laboratory of Neurodegenerative Diseases, Facultad de Ciencias de La Salud, Instituto de Ciencias Biom&#xe9;dicas, Universidad Aut&#xf3;noma de Chile, Santiago, Chile. rodrigo.quintanilla@uautonoma.cl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Transl Neurodegener</MedlineTA><NlmUniqueID>101591861</NlmUniqueID><ISSNLinking>2047-9158</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="Y">Huntington Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Cell reprogramming</Keyword><Keyword MajorTopicYN="N">Fibroblasts</Keyword><Keyword MajorTopicYN="N">Huntington&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Mitochondria</Keyword><Keyword MajorTopicYN="N">Mitochondrial dysfunction</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>5</Day><Hour>17</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35787292</ArticleId><ArticleId IdType="pmc">PMC9251940</ArticleId><ArticleId IdType="doi">10.1186/s40035-022-00308-y</ArticleId><ArticleId IdType="pii">10.1186/s40035-022-00308-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gorman AM. Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J Cell Mol Med. 2008;12:2263&#x2013;2280. doi: 10.1111/j.1582-4934.2008.00402.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2008.00402.x</ArticleId><ArticleId IdType="pmc">PMC4514105</ArticleId><ArticleId IdType="pubmed">18624755</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim GH, Kim JE, Rhie SJ, Yoon S. The role of oxidative stress in neurodegenerative diseases. Exp Neurobiology. 2015;24:325&#x2013;340. doi: 10.5607/en.2015.24.4.325.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2015.24.4.325</ArticleId><ArticleId IdType="pmc">PMC4688332</ArticleId><ArticleId IdType="pubmed">26713080</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15:565&#x2013;581. doi: 10.1038/s41582-019-0244-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0244-7</ArticleId><ArticleId IdType="pubmed">31501588</ArticleId></ArticleIdList></Reference><Reference><Citation>Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990&#x2013;2016: a systematic analysis for the Global Burden of Disease Study. Lancet Neurol. 2019;18:59&#x2013;480. doi: 10.1016/S1474-4422(18)30499-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30499-X</ArticleId><ArticleId IdType="pmc">PMC6459001</ArticleId><ArticleId IdType="pubmed">30879893</ArticleId></ArticleIdList></Reference><Reference><Citation>Desler C, Lillenes MS, T&#xf8;njum T, Rasmussen LJ. The Role of mitochondrial dysfunction in the progression of Alzheimer&#x2019;s disease. Curr Med Chem. 2019;25:578&#x2013;5587. doi: 10.2174/0929867324666170616110111.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867324666170616110111</ArticleId><ArticleId IdType="pmc">PMC6446443</ArticleId><ArticleId IdType="pubmed">28618998</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyle A, Anugrha H, Kurzawa-Akanbi M, Yarnall A, Burn D, Hudson G. Reduced mitochondrial DNA copy number is a biomarker of Parkinson&#x2019;s disease. Neurobiol Aging. 2016;38:16.e7&#x2013;216.e10. doi: 10.1016/j.neurobiolaging.2015.10.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.10.033</ArticleId><ArticleId IdType="pmc">PMC4759605</ArticleId><ArticleId IdType="pubmed">26639155</ArticleId></ArticleIdList></Reference><Reference><Citation>Acevedo-Torres K, Berr&#xed;os L, Rosario N, Dufault V, Skatchkov S, Eaton MJ, et al. Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington&#x2019;s disease. DNA Repair. 2009;8:26&#x2013;136. doi: 10.1016/j.dnarep.2008.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dnarep.2008.09.004</ArticleId><ArticleId IdType="pmc">PMC3268004</ArticleId><ArticleId IdType="pubmed">18935984</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi P, Gal J, Kwinter DM, Liu X, Zhu H. Mitochondrial dysfunction in amyotrophic lateral sclerosis. Biochim Biophys Acta. 2010;1802:5&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790551</ArticleId><ArticleId IdType="pubmed">19715760</ArticleId></ArticleIdList></Reference><Reference><Citation>Johri A, Bea MF. Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Ther. 2012;342(3):619&#x2013;630. doi: 10.1124/jpet.112.192138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.112.192138</ArticleId><ArticleId IdType="pmc">PMC3422529</ArticleId><ArticleId IdType="pubmed">22700435</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MY, Sheng ZH. Regulation of mitochondrial transport in neurons. Exp Cell Res. 2015;334:5&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4433773</ArticleId><ArticleId IdType="pubmed">25612908</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Xiong GJ, Huang N, Sheng ZH. The cross-talk of energy sensing and mitochondrial anchoring sustains synaptic efficacy by maintaining presynaptic metabolism. Nat Metabolism. 2020;2:077&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7572785</ArticleId><ArticleId IdType="pubmed">33020662</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnb&#xe4;ck A, Pavlov PF, Mansory M, Gonze P, Marli&#xe8;re N, Winblad B, et al. Mitochondrial dysfunction in a transgenic mouse model expressing human amyloid precursor protein (APP) with the Arctic mutation. J Neurochem. 2016;136(3):497&#x2013;502. doi: 10.1111/jnc.13410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13410</ArticleId><ArticleId IdType="pubmed">26500157</ArticleId></ArticleIdList></Reference><Reference><Citation>Stichel CC, Zhu XR, Bader V, Linnartz B, Schmidt S, L&#xfc;bbert H. Mono- and double-mutant mouse models of Parkinson&#x2019;s disease display severe mitochondrial damage. Hum Mol Genet. 2007;16:377&#x2013;2393. doi: 10.1093/hmg/ddm083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm083</ArticleId><ArticleId IdType="pubmed">17412759</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefa U, Jeong N, Song I, Chung HJ, Kim D, Jung J, et al. Mitophagy links oxidative stress conditions and neurodegenerative diseases. Neural Regen Res. 2019;14:49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375051</ArticleId><ArticleId IdType="pubmed">30688256</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers RS, Tungtur S, Tanaka T, Nadeau LL, Badawi Y, Wang H, et al. Impaired mitophagy plays a role in denervation of neuromuscular junctions in ALS mice. Front Neurosci. 2017;11:73. doi: 10.3389/fnins.2017.00473.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00473</ArticleId><ArticleId IdType="pmc">PMC5575151</ArticleId><ArticleId IdType="pubmed">28890682</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabezas-Opazo FA, Vergara-Pulgar K, P&#xe9;rez MJ, Jara C, Osorio-Fuentealba C, Quintanilla RA. Mitochondrial dysfunction contributes to the pathogenesis of Alzheimer&#x2019;s disease. Oxid Med Cell Longev. 2015;2015:12. doi: 10.1155/2015/509654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/509654</ArticleId><ArticleId IdType="pmc">PMC4499633</ArticleId><ArticleId IdType="pubmed">26221414</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, et al. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann Neurol. 2000;47:1&#x2013;86. doi: 10.1002/1531-8249(200001)47:1&lt;80::AID-ANA13&gt;3.0.CO;2-K.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(200001)47:1&lt;80::AID-ANA13&gt;3.0.CO;2-K</ArticleId><ArticleId IdType="pubmed">10632104</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TM, Golde TE, Lagier-Tourenne C. Animal models of neurodegenerative diseases. Nat Neurosci. 2018;21:370&#x2013;1379. doi: 10.1038/s41593-018-0236-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0236-8</ArticleId><ArticleId IdType="pmc">PMC6615039</ArticleId><ArticleId IdType="pubmed">30250265</ArticleId></ArticleIdList></Reference><Reference><Citation>Altanbyek V, Cha SJ, Kang GU, Im DS, Lee S, Kim HJ, et al. Imbalance of mitochondrial dynamics in Drosophila models of amyotrophic lateral sclerosis. Biochem Bioph Res. 2016;481:59&#x2013;264. doi: 10.1016/j.bbrc.2016.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.11.018</ArticleId><ArticleId IdType="pubmed">27810362</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvatici R, Marani L, Marino S, Siniscalchi A. In vitro mitochondrial failure and oxidative stress mimic biochemical features of Alzheimer disease. Neurochem Int. 2013;63:12&#x2013;120. doi: 10.1016/j.neuint.2013.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2013.05.005</ArticleId><ArticleId IdType="pubmed">23722080</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, et al. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med. 1999;5:01&#x2013;106. doi: 10.1038/4789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/4789</ArticleId><ArticleId IdType="pubmed">9883847</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H. Overexpression of &#x3b1;-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of &#x3b1;-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson&#x2019;s disease. J Neurochem. 2004;91:51&#x2013;461. doi: 10.1111/j.1471-4159.2004.02728.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02728.x</ArticleId><ArticleId IdType="pubmed">15447678</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, Ohno M. Mitochondrial dysfunction and accumulation of the &#x3b2;-secretase-cleaved C-terminal fragment of APP in Alzheimer&#x2019;s disease transgenic mice. Neurobiol Dis. 2012;45:17&#x2013;424. doi: 10.1016/j.nbd.2011.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.09.001</ArticleId><ArticleId IdType="pmc">PMC3225635</ArticleId><ArticleId IdType="pubmed">21933711</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Burgess JD, Faroqi AH, DeMeo NN, Fiesel FC, Springer W, et al. Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway. Mol Neurodegener. 2020;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6956494</ArticleId><ArticleId IdType="pubmed">31931835</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosi G, Ghezzi C, Sepe S, Milanese C, Payan-Gomez C, Bombardieri CR, et al. Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson&#x2019;s disease. Biochim Biophys Acta. 2014;1842:385&#x2013;1394.</Citation><ArticleIdList><ArticleId IdType="pubmed">24854107</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk K, Gennings C, Hupf JC, Tadesse S, D&#x2019;Aurelio M, Kawamata H, et al. Bioenergetic markers in skin fibroblasts of sporadic ALS and PLS patients. Ann Neurol. 2014;76:20&#x2013;624. doi: 10.1002/ana.24244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24244</ArticleId><ArticleId IdType="pmc">PMC4192005</ArticleId><ArticleId IdType="pubmed">25090982</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GA, Jansson J, Rocha EM, Osborn T, Hallett PJ, Isacson O. Fibroblast biomarkers of sporadic Parkinson&#x2019;s disease and LRRK2 kinase inhibition. Mol Neurobiol. 2016;53:161&#x2013;5177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5012155</ArticleId><ArticleId IdType="pubmed">26399642</ArticleId></ArticleIdList></Reference><Reference><Citation>Antony PMA, Kondratyeva O, Mommaerts K, Ostaszewski M, Sokolowska K, Baumuratov AS, et al. Fibroblast mitochondria in idiopathic Parkinson&#x2019;s disease display morphological changes and enhanced resistance to depolarization. Sci Rep. 2020;10:569. doi: 10.1038/s41598-020-58505-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-58505-6</ArticleId><ArticleId IdType="pmc">PMC6994699</ArticleId><ArticleId IdType="pubmed">32005875</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez MJ, Ponce DP, Osorio-Fuentealba C, Behrens MI, Quintanilla RA. Mitochondrial bioenergetics is altered in fibroblasts from patients with sporadic Alzheimer&#x2019;s disease. Front Neurosci. 2017;11:53. doi: 10.3389/fnins.2017.00553.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00553</ArticleId><ArticleId IdType="pmc">PMC5635042</ArticleId><ArticleId IdType="pubmed">29056898</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Zhang KY, Kariawasam R, Bax M, Fifita JA, Ooi L, et al. Evaluation of skin fibroblasts from amyotrophic lateral sclerosis patients for the rapid study of pathological features. Neurotox Res. 2015;28:38&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">26013250</ArticleId></ArticleIdList></Reference><Reference><Citation>Victor MB, Richner M, Hermanstyne TO, Ransdell JL, Sobieski C, Deng PY, et al. Generation of human striatal neurons by microrna-dependent direct conversion of fibroblasts. Neuron. 2014;84:11&#x2013;323. doi: 10.1016/j.neuron.2014.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.10.016</ArticleId><ArticleId IdType="pmc">PMC4223654</ArticleId><ArticleId IdType="pubmed">25374357</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Li F, Stubblefield EA, Blanchard B, Richards TL, Larson GA, et al. Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. Cell Res. 2012;22:21&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3271588</ArticleId><ArticleId IdType="pubmed">22105488</ArticleId></ArticleIdList></Reference><Reference><Citation>Caiazzo M, Dell&#x2019;Anno MT, Dvoretskova E, Lazarevic D, Taverna S, Leo D, et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature. 2011;476:24&#x2013;227. doi: 10.1038/nature10284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10284</ArticleId><ArticleId IdType="pubmed">21725324</ArticleId></ArticleIdList></Reference><Reference><Citation>Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, S&#xfc;dhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature. 2010;463:035&#x2013;1041. doi: 10.1038/nature08797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08797</ArticleId><ArticleId IdType="pmc">PMC2829121</ArticleId><ArticleId IdType="pubmed">20107439</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Chen R, Wu X, Zhao Y, Fan Y, Xiao Z, et al. Rapid and efficient conversion of human fibroblasts into functional neurons by small molecules. Stem Cell Rep. 2019;13:62&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6893066</ArticleId><ArticleId IdType="pubmed">31631018</ArticleId></ArticleIdList></Reference><Reference><Citation>Deus CM, Pereira SP, Cunha-Oliveira T, Pereira FB, Raimundo N, Oliveira PJ. Mitochondrial remodeling in human skin fibroblasts from sporadic male Parkinson&#x2019;s disease patients uncovers metabolic and mitochondrial bioenergetic defects. Biochim Biophys Acta. 2020;1866:65615.</Citation><ArticleIdList><ArticleId IdType="pubmed">31759069</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira SP, Deus CM, Serafim TL, Cunha-Oliveira T, Oliveira PJ. Metabolic and phenotypic characterization of human skin fibroblasts after forcing oxidative capacity. Toxicol Sci. 2018;164:91&#x2013;204. doi: 10.1093/toxsci/kfy068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/toxsci/kfy068</ArticleId><ArticleId IdType="pubmed">29945227</ArticleId></ArticleIdList></Reference><Reference><Citation>Magini A, Urbanelli L, Ciccarone V, Tancini B, Polidoro M, Timperio AM, et al. Fibroblasts from PS1 mutated pre-symptomatic subjects and Alzheimer&#x2019;s disease patients share a unique protein levels profile. J Alzheimers Dis. 2010;21:31&#x2013;444. doi: 10.3233/JAD-2010-091522.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-091522</ArticleId><ArticleId IdType="pubmed">20555143</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez MJ, Ponce DP, Aranguiz A, Behrens MI, Quintanilla RA. Mitochondrial permeability transition pore contributes to mitochondrial dysfunction in fibroblasts of patients with sporadic Alzheimer&#x2019;s disease. Redox Biol. 2018;19:90&#x2013;300. doi: 10.1016/j.redox.2018.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2018.09.001</ArticleId><ArticleId IdType="pmc">PMC6129674</ArticleId><ArticleId IdType="pubmed">30199818</ArticleId></ArticleIdList></Reference><Reference><Citation>del Hoyo P, Garc&#xed;a-Redondo A, de Bustos F, Molina JA, Sayed Y, Alonso-Navarro H, et al. Oxidative stress in skin fibroblasts cultures of patients with Huntington&#x2019;s disease. Neurochem Res. 2006;31:103&#x2013;1109. doi: 10.1007/s11064-005-9236-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-005-9236-7</ArticleId><ArticleId IdType="pubmed">16944322</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano N, Catalani A, Lattante S, Belardo A, Proietti S, Bertini L, et al. ALS skin fibroblasts reveal oxidative stress and ERK1/2-mediated cytoplasmic localization of TDP-43. Cell Signal. 2020;70:09591. doi: 10.1016/j.cellsig.2020.109591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2020.109591</ArticleId><ArticleId IdType="pubmed">32126264</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;hlbrandt W. Structure and function of mitochondrial membrane protein complexes. BMC Biol. 2015;13:9. doi: 10.1186/s12915-015-0201-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12915-015-0201-x</ArticleId><ArticleId IdType="pmc">PMC4625866</ArticleId><ArticleId IdType="pubmed">26515107</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliek AM, van der Shen Q, Kawajiri S. Mechanisms of mitochondrial fission and fusion. Cold Spring Harb Perspect Biol. 2013;5:a011072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3660830</ArticleId><ArticleId IdType="pubmed">23732471</ArticleId></ArticleIdList></Reference><Reference><Citation>Detmer SA, Chan DC. Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Bio. 2007;8:70&#x2013;879. doi: 10.1038/nrm2275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2275</ArticleId><ArticleId IdType="pubmed">17928812</ArticleId></ArticleIdList></Reference><Reference><Citation>Martorell-Riera A, Segarra-Mondejar M, Mu&#xf1;oz JP, Ginet V, Olloquequi J, P&#xe9;rez-Clausell J, et al. Mfn2 downregulation in excitotoxicity causes mitochondrial dysfunction and delayed neuronal death. EMBO J. 2014;33:388&#x2013;2407. doi: 10.15252/embj.201488327.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201488327</ArticleId><ArticleId IdType="pmc">PMC4253527</ArticleId><ArticleId IdType="pubmed">25147362</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa JS, D&#x2019;Imprima E, Vonck J. Membrane protein complexes: structure and function. Subcell Biochem. 2018;87:67&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">29464561</ArticleId></ArticleIdList></Reference><Reference><Citation>Trumpower BL, Gennis RB. Energy transduction by cytochrome complexes in mitochondrial and bacterial respiration: the enzymology of coupling electron transfer reactions to transmembrane proton translocation. Annu Rev Biochem. 1994;63:75&#x2013;716. doi: 10.1146/annurev.bi.63.070194.003331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.bi.63.070194.003331</ArticleId><ArticleId IdType="pubmed">7979252</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:13. doi: 10.1042/BJ20081386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20081386</ArticleId><ArticleId IdType="pmc">PMC2605959</ArticleId><ArticleId IdType="pubmed">19061483</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy PH. Role of mitochondria in neurodegenerative diseases: mitochondria as a therapeutic target in neurodegenerative diseases. CNS Spectr. 2009;14:18. doi: 10.1109/MSPEC.2009.4770601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/MSPEC.2009.4770601</ArticleId><ArticleId IdType="pmc">PMC3056539</ArticleId><ArticleId IdType="pubmed">19890241</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;gerh&#xe4;ll C. Succinate: quinone oxidoreductases. Biochim Biophys Acta BBA Bioenerg. 1997;1320:07&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">9210286</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher P, Schubert D. Signaling by reactive oxygen species in the nervous system. Cell Mol Life Sci Cmls. 2000;57:287&#x2013;1305.</Citation><ArticleIdList><ArticleId IdType="pubmed">11028919</ArticleId></ArticleIdList></Reference><Reference><Citation>Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. 2012;48:58&#x2013;167. doi: 10.1016/j.molcel.2012.09.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2012.09.025</ArticleId><ArticleId IdType="pmc">PMC3484374</ArticleId><ArticleId IdType="pubmed">23102266</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteras N, Abramov AY. Mitochondrial calcium deregulation in the mechanism of beta-amyloid and tau pathology. Cells. 2020;9:135. doi: 10.3390/cells9092135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9092135</ArticleId><ArticleId IdType="pmc">PMC7564294</ArticleId><ArticleId IdType="pubmed">32967303</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchi ED, Bonora M, Giorgi C, Pinton P. The mitochondrial permeability transition pore is a dispensable element for mitochondrial calcium efflux. Cell Calcium. 2014;56:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4074345</ArticleId><ArticleId IdType="pubmed">24755650</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgi C, Marchi S, Pinton P. The machineries, regulation and cellular functions of mitochondrial calcium. Nat Rev Mol Cell Bio. 2018;19:13&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">30143745</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefani DD, Patron M, Rizzuto R. Structure and function of the mitochondrial calcium uniporter complex. Biochim Biophys Acta. 2015;1853(9):2006&#x2013;2011. doi: 10.1016/j.bbamcr.2015.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2015.04.008</ArticleId><ArticleId IdType="pmc">PMC4522341</ArticleId><ArticleId IdType="pubmed">25896525</ArticleId></ArticleIdList></Reference><Reference><Citation>Mnatsakanyan N, Beutner G, Porter GA, Alavian KN, Jonas EA. Physiological roles of the mitochondrial permeability transition pore. J Bioenerg Biomembr. 2017;49:3&#x2013;25. doi: 10.1007/s10863-016-9652-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10863-016-9652-1</ArticleId><ArticleId IdType="pmc">PMC4981558</ArticleId><ArticleId IdType="pubmed">26868013</ArticleId></ArticleIdList></Reference><Reference><Citation>Marland JRK, Hasel P, Bonnycastle K, Cousin MA. Mitochondrial calcium uptake modulates synaptic vesicle endocytosis in central nerve terminals. J Biol Chem. 2016;291:080&#x2013;2086. doi: 10.1074/jbc.M115.686956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.686956</ArticleId><ArticleId IdType="pmc">PMC4732196</ArticleId><ArticleId IdType="pubmed">26644474</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo-Rodriguez M, Hou SS, Snyder AC, Kharitonova EK, Russ AN, Das S, et al. Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer&#x2019;s disease. Nat Commun. 2020;11:146. doi: 10.1038/s41467-020-16074-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-16074-2</ArticleId><ArticleId IdType="pmc">PMC7195480</ArticleId><ArticleId IdType="pubmed">32358564</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintanilla RA, Johnson GVW. Role of mitochondrial dysfunction in the pathogenesis of Huntington&#x2019;s disease. Brain Res Bull. 2009;80:42&#x2013;247. doi: 10.1016/j.brainresbull.2009.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2009.07.010</ArticleId><ArticleId IdType="pmc">PMC2757461</ArticleId><ArticleId IdType="pubmed">19622387</ArticleId></ArticleIdList></Reference><Reference><Citation>Begley JG, Duan W, Chan S, Duff K, Mattson MP. Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of Presenilin-1 mutant mice. J Neurochem. 1999;72:030&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037474</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinkova-Kostova AT, Abramov AY. The emerging role of Nrf2 in mitochondrial function. Free Radical Bio Med. 2015;88:79&#x2013;188. doi: 10.1016/j.freeradbiomed.2015.04.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.04.036</ArticleId><ArticleId IdType="pmc">PMC4726722</ArticleId><ArticleId IdType="pubmed">25975984</ArticleId></ArticleIdList></Reference><Reference><Citation>Villavicencio-Tejo F, Quintanilla RA. Contribution of the Nrf2 pathway on oxidative damage and mitochondrial failure in Parkinson and Alzheimer&#x2019;s disease. Antioxidants. 2021;10:069. doi: 10.3390/antiox10071069.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10071069</ArticleId><ArticleId IdType="pmc">PMC8301100</ArticleId><ArticleId IdType="pubmed">34356302</ArticleId></ArticleIdList></Reference><Reference><Citation>Villavicencio-Tejo F, Olesen MA, Ar&#xe1;nguiz A, Quintanilla RA. Activation of the Nrf2 pathway prevents mitochondrial dysfunction induced by caspase-3 cleaved tau: implications for Alzheimer&#x2019;s disease. Antioxidants. 2022;11:15. doi: 10.3390/antiox11030515.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox11030515</ArticleId><ArticleId IdType="pmc">PMC8944569</ArticleId><ArticleId IdType="pubmed">35326165</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara C, Ar&#xe1;nguiz A, Cerpa W, Tapia-Rojas C, Quintanilla RA. Genetic ablation of tau improves mitochondrial function and cognitive abilities in the hippocampus. Redox Biol. 2018;18:79&#x2013;294. doi: 10.1016/j.redox.2018.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2018.07.010</ArticleId><ArticleId IdType="pmc">PMC6072970</ArticleId><ArticleId IdType="pubmed">30077079</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A, K&#xfc;gler S, Lastres-Becker I. Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy. Redox Biol. 2018;14:22&#x2013;534. doi: 10.1016/j.redox.2017.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2017.10.010</ArticleId><ArticleId IdType="pmc">PMC5681345</ArticleId><ArticleId IdType="pubmed">29121589</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson TP, Johnson DA, Johnson JA. Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity. Neurotoxicology. 2012;33:72&#x2013;279. doi: 10.1016/j.neuro.2012.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuro.2012.01.015</ArticleId><ArticleId IdType="pmc">PMC3521526</ArticleId><ArticleId IdType="pubmed">22342405</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Li WX, Dai SX, Guo YC, Han FF, Zheng JJ, et al. Meta-analysis of Parkinson&#x2019;s disease and Alzheimer&#x2019;s disease revealed commonly impaired pathways and dysregulation of NRF2-dependent genes. J Alzheimers Dis. 2017;56:525&#x2013;1539.</Citation><ArticleIdList><ArticleId IdType="pubmed">28222515</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7:37&#x2013;152. doi: 10.1038/nrneurol.2011.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.2</ArticleId><ArticleId IdType="pmc">PMC3339565</ArticleId><ArticleId IdType="pubmed">21304480</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahn H. Memory loss in Alzheimer&#x2019;s disease. Dialogues Clin Neurosc. 2013;15:45&#x2013;454. doi: 10.31887/DCNS.2013.15.4/hjahn.</Citation><ArticleIdList><ArticleId IdType="doi">10.31887/DCNS.2013.15.4/hjahn</ArticleId><ArticleId IdType="pmc">PMC3898682</ArticleId><ArticleId IdType="pubmed">24459411</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HC, Jiang ZF. Accumulated amyloid-&#x3b2; peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer&#x2019;s disease. J Alzheimers Dis. 2009;16:5&#x2013;27. doi: 10.3233/JAD-2009-0960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2009-0960</ArticleId><ArticleId IdType="pubmed">19158417</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer&#x2019;s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:92&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417794</ArticleId><ArticleId IdType="pubmed">27012484</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez MJ, Jara C, Mu&#xf1;oz-Urrutia E, Quintanilla RA. New targets for diagnosis and treatment against Alzheimer&#x2019;s disease: the mitochondrial approach. In: Moretti DV, editor. Update on Dementia. London: IntechOpen; 2016.</Citation></Reference><Reference><Citation>Quntanilla RA, Tapia-Monsalves C. The role of mitochondrial impairment in alzheimer&#xb4;s disease neurodegeneration: the tau connection. Curr Neuropharmacol. 2020;18:076&#x2013;1091. doi: 10.2174/1570159X18666200525020259.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X18666200525020259</ArticleId><ArticleId IdType="pmc">PMC7709157</ArticleId><ArticleId IdType="pubmed">32448104</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy PH, Tripathi R, Troung Q, Tirumala K, Reddy TP, Anekonda V, et al. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer&#x2019;s disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta. 2012;1822(5):639&#x2013;649. doi: 10.1016/j.bbadis.2011.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2011.10.011</ArticleId><ArticleId IdType="pmc">PMC3272314</ArticleId><ArticleId IdType="pubmed">22037588</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Su B, Lee H, Li X, Perry G, Smith MA, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer&#x2019;s disease. J Neurosci. 2009;29:090&#x2013;9103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735241</ArticleId><ArticleId IdType="pubmed">19605646</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Yin J, Ma X, Zhao F, Siedlak SL, Wang Z, et al. Inhibition of mitochondrial fragmentation protects against Alzheimer&#x2019;s disease in rodent model. Hum Mol Genet. 2017;26:118&#x2013;4131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886251</ArticleId><ArticleId IdType="pubmed">28973308</ArticleId></ArticleIdList></Reference><Reference><Citation>Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer&#x2019;s disease: implications for neuronal damage. Hum Mol Genet. 2011;20:495&#x2013;2509. doi: 10.1093/hmg/ddr139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr139</ArticleId><ArticleId IdType="pmc">PMC3109997</ArticleId><ArticleId IdType="pubmed">21459773</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SW, Zhang D, Chung HD, Zassenhaus HP. The frequency of point mutations in mitochondrial DNA is elevated in the Alzheimer&#x2019;s Brain. Biochem Bioph Res. 2000;273:03&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">10873587</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer I, Zierz S, M&#xf6;ller H. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging. 2000;21:55&#x2013;462. doi: 10.1016/S0197-4580(00)00112-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(00)00112-3</ArticleId><ArticleId IdType="pubmed">10858595</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer&#x2019;s disease.pdf. J Neurochem. 1994;63:179&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">7964738</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks WM, Lynch PJ, Ingle CC, Hatton A, Emson PC, Faull RLM, et al. Gene expression profiles of metabolic enzyme transcripts in Alzheimer&#x2019;s disease. Brain Res. 2007;1127:27&#x2013;135. doi: 10.1016/j.brainres.2006.09.106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2006.09.106</ArticleId><ArticleId IdType="pubmed">17109828</ArticleId></ArticleIdList></Reference><Reference><Citation>Stojakovic A, Chang SY, Nesbitt J, Pichurin NP, Ostroot MA, Aikawa T, et al. Partial inhibition of mitochondrial complex I reduces tau pathology and improves energy homeostasis and synaptic function in 3xTg-AD mice. J Alzheimer&#x2019;s Dis. 2021;79:35&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7902954</ArticleId><ArticleId IdType="pubmed">33285637</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintanilla RA, Matthews-Roberson TA, Dolan PJ, Johnson GVW. Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer&#x2019;disease. J Biol Chem. 2009;284:8754&#x2013;18766. doi: 10.1074/jbc.M808908200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808908200</ArticleId><ArticleId IdType="pmc">PMC2707209</ArticleId><ArticleId IdType="pubmed">19389700</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez MJ, Vergara-Pulgar K, Jara C, Cabezas-Opazo F, Quintanilla RA. Caspase-cleaved tau impairs mitochondrial dynamics in Alzheimer&#x2019;s disease. Mol Neurobiol. 2018;55:004&#x2013;1018. doi: 10.1007/s12035-017-0385-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0385-x</ArticleId><ArticleId IdType="pubmed">28084594</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Sierra F, Mondrag&#xf3;n-Rodr&#xed;guez S, Basurto-Islas G. Truncation of Tau protein and its pathological significance in Alzheimer&#x2019;s disease. J Alzheimers Dis. 2008;14:01&#x2013;9. doi: 10.3233/JAD-2008-14407.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2008-14407</ArticleId><ArticleId IdType="pubmed">18688090</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintanilla RA, Tapia-Monsalves C, Vergara EH, P&#xe9;rez MJ, Aranguiz A. Truncated tau induces mitochondrial transport failure through the impairment of TRAK2 protein and bioenergetics decline in neuronal cells. Front Cell Neurosci. 2020;14:75. doi: 10.3389/fncel.2020.00175.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.00175</ArticleId><ArticleId IdType="pmc">PMC7406829</ArticleId><ArticleId IdType="pubmed">32848607</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Bai F. The association of tau with mitochondrial dysfunction in Alzheimer&#x2019;s disease. Front Neurosci. 2018;12:63. doi: 10.3389/fnins.2018.00163.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00163</ArticleId><ArticleId IdType="pmc">PMC5874499</ArticleId><ArticleId IdType="pubmed">29623026</ArticleId></ArticleIdList></Reference><Reference><Citation>David DC, Hauptmann S, Scherping I, Schuessel K, Keil U, Rizzu P, et al. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem. 2005;280:3802&#x2013;23814. doi: 10.1074/jbc.M500356200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M500356200</ArticleId><ArticleId IdType="pubmed">15831501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG. Chapter 25 Tauopathies. Handb Clin Neurol. 2017;145:55&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">28987182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandimalla R, Manczak M, Fry D, Suneetha Y, Sesaki H, Reddy PH. Reduced dynamin-related protein 1 protects against phosphorylated Tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer&#x2019;s disease. Hum Mol Genet. 2016;25:881&#x2013;4897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6078590</ArticleId><ArticleId IdType="pubmed">28173111</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan X, Huang S, Wu L, Wang Y, Hu G, Li G, et al. Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer&#x2019;s disease cybrid cell. Biochim Biophys Acta. 2014;1842:20&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3991235</ArticleId><ArticleId IdType="pubmed">24252614</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadiya P, Kolmetzky DW, Tomar D, Meco AD, Lombardi AA, Lambert JP, et al. Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer&#x2019;s disease. Nat Commun. 2019;10:885. doi: 10.1038/s41467-019-11813-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11813-6</ArticleId><ArticleId IdType="pmc">PMC6715724</ArticleId><ArticleId IdType="pubmed">31467276</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan KC, Ashkavand Z, Norman KR. The role of mitochondrial calcium homeostasis in Alzheimer&#x2019;s and related diseases. Int J Mol Sci. 2020;21:153. doi: 10.3390/ijms21239153.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21239153</ArticleId><ArticleId IdType="pmc">PMC7730848</ArticleId><ArticleId IdType="pubmed">33271784</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988;1:23&#x2013;634. doi: 10.1016/0896-6273(88)90162-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(88)90162-6</ArticleId><ArticleId IdType="pubmed">2908446</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosie KA, King AE, Blizzard CA, Vickers JC, Dickson TC. Chronic excitotoxin-induced axon degeneration in a compartmented neuronal culture model. ASN Neuro. 2012;4:e00076. doi: 10.1042/AN20110031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/AN20110031</ArticleId><ArticleId IdType="pmc">PMC3284768</ArticleId><ArticleId IdType="pubmed">22356284</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaels RL, Rochman SL. Glutamate neurotoxicity in vitro- antagonist pharmacology and intracellular calcium concentrations. J Neurosci. 1990;10:83&#x2013;292. doi: 10.1523/JNEUROSCI.10-01-00283.1990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.10-01-00283.1990</ArticleId><ArticleId IdType="pmc">PMC6570346</ArticleId><ArticleId IdType="pubmed">1967639</ArticleId></ArticleIdList></Reference><Reference><Citation>Pivovarova NB, Nguyen HV, Winters CA, Brantner CA, Smith CL, Andrews SB. Excitotoxic calcium overload in a subpopulation of mitochondria triggers delayed death in hippocampal neurons. J Neurosci. 2004;24:611&#x2013;5622. doi: 10.1523/JNEUROSCI.0531-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0531-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729327</ArticleId><ArticleId IdType="pubmed">15201334</ArticleId></ArticleIdList></Reference><Reference><Citation>Schinder AF, Olson EC, Spitzer NC, Montal M. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci. 1996;16:125&#x2013;6133. doi: 10.1523/JNEUROSCI.16-19-06125.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.16-19-06125.1996</ArticleId><ArticleId IdType="pmc">PMC6579180</ArticleId><ArticleId IdType="pubmed">8815895</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Mart&#xed;n T, Pooler AM, Lau DHW, M&#xf3;rotz GM, Vos KJD, Gilley J, et al. Reduced number of axonal mitochondria and tau hypophosphorylation in mouse P301L tau knockin neurons. Neurobiol Dis. 2016;85:10. doi: 10.1016/j.nbd.2015.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.10.007</ArticleId><ArticleId IdType="pmc">PMC4684147</ArticleId><ArticleId IdType="pubmed">26459111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandimalla R, Manczak M, Yin X, Wang R, Reddy PH. Hippocampal phosphorylated tau induced cognitive decline, dendritic spine loss and mitochondrial abnormalities in a mouse model of Alzheimer&#x2019;s disease. Hum Mol Genet. 2017;27:1&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886218</ArticleId><ArticleId IdType="pubmed">29040533</ArticleId></ArticleIdList></Reference><Reference><Citation>Krako N, Magnifico MC, Arese M, Meli G, Forte E, Lecci A, et al. Characterization of mitochondrial dysfunction in the 7PA2 cell model of Alzheimer&#x2019;s disease. J Alzheimers Dis. 2013;37:47&#x2013;758. doi: 10.3233/JAD-130728.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-130728</ArticleId><ArticleId IdType="pubmed">23948918</ArticleId></ArticleIdList></Reference><Reference><Citation>Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS. Early deficits in synaptic mitochondria in an Alzheimer&#x2019;s disease mouse model. Proc Natl Acad Sci U S A. 2010;107:8670&#x2013;18675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2972922</ArticleId><ArticleId IdType="pubmed">20937894</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintanilla RA, Dolan PJ, Jin YN, Johnson GVW. Truncated tau and A&#x3b2; cooperatively impair mitochondria in primary neurons. Neurobiol Aging. 2012;33:1925&#x2013;61935. doi: 10.1016/j.neurobiolaging.2011.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.02.007</ArticleId><ArticleId IdType="pmc">PMC3140623</ArticleId><ArticleId IdType="pubmed">21450370</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck SJ, Guo L, Phensy A, Tian J, Wang L, Tandon N, et al. Deregulation of mitochondrial F1FO-ATP synthase via OSCP in Alzheimer&#x2019;s disease. Nat Commun. 2016;7:1483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494197</ArticleId><ArticleId IdType="pubmed">27151236</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer&#x2019;s pathology in female mouse model of Alzheimer&#x2019;s diseasepdf. Proc Natl Acad Sci U S A. 2009;106:4670&#x2013;4675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732886</ArticleId><ArticleId IdType="pubmed">19667196</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande A, Mina E, Glabe C, Busciglio J. Different conformations of amyloid &#x3b2; induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci. 2006;26:011&#x2013;6018. doi: 10.1523/JNEUROSCI.1189-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1189-06.2006</ArticleId><ArticleId IdType="pmc">PMC6675207</ArticleId><ArticleId IdType="pubmed">16738244</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie H, Guan J, Borrelli LA, Xu J, Serrano-Pozo A, Bacskai BJ. Mitochondrial alterations near amyloid plaques in an Alzheimer&#x2019;s disease mouse model. J Neurosci. 2013;33:7042&#x2013;17051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3807029</ArticleId><ArticleId IdType="pubmed">24155308</ArticleId></ArticleIdList></Reference><Reference><Citation>Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA. Parkinson&#x2019;s Disease. Subcell Biochem. 2012;65:89&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4372387</ArticleId><ArticleId IdType="pubmed">23225012</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe1;radi C. Clinical features of Parkinson&#x2019;s disease: the evolution of critical symptoms. Biology. 2020;9:03. doi: 10.3390/biology9050103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology9050103</ArticleId><ArticleId IdType="pmc">PMC7285080</ArticleId><ArticleId IdType="pubmed">32438686</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Han X, Li X, Song Q, Lu M, Jia M, et al. MicroRNA-212-5p prevents dopaminergic neuron death by inhibiting SIRT2 in MPTP-induced mouse model of Parkinson&#x2019;s disease. Front Mol Neurosci. 2018;11:81. doi: 10.3389/fnmol.2018.00081.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00081</ArticleId><ArticleId IdType="pmc">PMC6193094</ArticleId><ArticleId IdType="pubmed">30364275</ArticleId></ArticleIdList></Reference><Reference><Citation>Naoi M, Maruyama W. Cell death of dopamine neurons in aging and Parkinson&#x2019;s disease. Mech Ageing Dev. 1999;111:75&#x2013;188. doi: 10.1016/S0047-6374(99)00064-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0047-6374(99)00064-0</ArticleId><ArticleId IdType="pubmed">10656535</ArticleId></ArticleIdList></Reference><Reference><Citation>Callizot N, Combes M, Henriques A, Poindron P. Necrosis, apoptosis, necroptosis, three modes of action of dopaminergic neuron neurotoxins. PLoS ONE. 2019;14:e0215277. doi: 10.1371/journal.pone.0215277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0215277</ArticleId><ArticleId IdType="pmc">PMC6483187</ArticleId><ArticleId IdType="pubmed">31022188</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda T, Nakata Y, Mochizuki H. &#x3b1;-synuclein and neuronal cell death. Mol Neurobiol. 2013;47:66&#x2013;483. doi: 10.1007/s12035-012-8327-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-012-8327-0</ArticleId><ArticleId IdType="pmc">PMC3589663</ArticleId><ArticleId IdType="pubmed">22936307</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson&#x2019;s disease. Mov Disord Official J Mov Disord Soc. 2011;26:049&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">21626550</ArticleId></ArticleIdList></Reference><Reference><Citation>Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, et al. Missing pieces in the Parkinson&#x2019;s disease puzzle. Nat Med. 2010;16:53&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">20495568</ArticleId></ArticleIdList></Reference><Reference><Citation>Schapira AHV, Tolosa E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol. 2010;6:09&#x2013;317. doi: 10.1038/nrneurol.2010.52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2010.52</ArticleId><ArticleId IdType="pubmed">20479780</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed X, Bandr&#xe9;s-Ciga S, Blauwendraat C, Cookson MR. The role of monogenic genes in idiopathic Parkinson&#x2019;s disease. Neurobiol Dis. 2018;124:30&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6363864</ArticleId><ArticleId IdType="pubmed">30448284</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18:091&#x2013;1102. doi: 10.1016/S1474-4422(19)30320-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30320-5</ArticleId><ArticleId IdType="pmc">PMC8422160</ArticleId><ArticleId IdType="pubmed">31701892</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson&#x2019;s disease: progress and therapeutic implications: the genetics of PD. Movement Disord. 2013;28:4&#x2013;23. doi: 10.1002/mds.25249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25249</ArticleId><ArticleId IdType="pmc">PMC3578399</ArticleId><ArticleId IdType="pubmed">23389780</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy MK, Cookson MR. Mitochondrial quality control and dynamics in Parkinson&#x2019;s disease. Antioxid Redox Sign. 2012;16:69&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292751</ArticleId><ArticleId IdType="pubmed">21568830</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon HE, Paek SH. Mitochondrial dysfunction in Parkinson&#x2019;s disease. Exp Neurobiol. 2015;24:03&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4479806</ArticleId><ArticleId IdType="pubmed">26113789</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto M, Nissanka N, Moraes CT. Lack of Parkin anticipates the phenotype and affects mitochondrial morphology and mtDNA levels in a mouse model of Parkinson&#x2019;s disease. J Neurosci. 2018;38:042&#x2013;1053. doi: 10.1523/JNEUROSCI.1384-17.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1384-17.2017</ArticleId><ArticleId IdType="pmc">PMC5783961</ArticleId><ArticleId IdType="pubmed">29222404</ArticleId></ArticleIdList></Reference><Reference><Citation>Song L, McMackin M, Nguyen A, Cortopassi G. Parkin deficiency accelerates consequences of mitochondrial DNA deletions and Parkinsonism. Neurobiol Dis. 2017;100:1&#x2013;38. doi: 10.1016/j.nbd.2016.12.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.12.024</ArticleId><ArticleId IdType="pubmed">28042097</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong-Kee CJ, Sidorova E, Hanif A, Perera G, Nash JE. Mitochondrial dysfunction precedes other sub-cellular abnormalities in an in vitro model linked with cell death in Parkinson&#x2019;s disease. Neurotox Res. 2012;21:85&#x2013;194. doi: 10.1007/s12640-011-9259-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-011-9259-6</ArticleId><ArticleId IdType="pubmed">21773851</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharjee N, Borah A. Oxidative stress and mitochondrial dysfunction are the underlying events of dopaminergic neurodegeneration in homocysteine rat model of Parkinson&#x2019;s disease. Neurochem Int. 2016;48&#x2013;55:8&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">27732886</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, et al. Deficiencies in Complex I subunits of the respiratory chain in Parkinson&#x2019;s disease. Biochem Biophys Res Commun. 1989;163:450&#x2013;1455. doi: 10.1016/0006-291X(89)91141-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-291X(89)91141-8</ArticleId><ArticleId IdType="pubmed">2551290</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori N, Tanaka M, Ozawa T, Mizuno Y. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in parkinson&#x2019;s disease. Ann Neurol. 1991;30:63&#x2013;571. doi: 10.1002/ana.410300409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410300409</ArticleId><ArticleId IdType="pubmed">1665052</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and &#x3b1;-synuclein. Proc Natl Acad Sci U S A. 2005;102:413&#x2013;3418. doi: 10.1073/pnas.0409713102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0409713102</ArticleId><ArticleId IdType="pmc">PMC552938</ArticleId><ArticleId IdType="pubmed">15716361</ArticleId></ArticleIdList></Reference><Reference><Citation>Inden M, Kitamura Y, Abe M, Tamaki A, Takata K, Taniguchi T. Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice. Biol Pharm Bull. 2011;34:2&#x2013;96. doi: 10.1248/bpb.34.92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.34.92</ArticleId><ArticleId IdType="pubmed">21212524</ArticleId></ArticleIdList></Reference><Reference><Citation>Bov&#xe9; J, Perier C. Neurotoxin-based models of Parkinson&#x2019;s disease. Neuroscience. 2011;211:1&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">22108613</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xfc;newald A, Rygiel KA, Hepplewhite PD, Morris CM, Picard M, Turnbull DM. Mitochondrial DNA depletion in respiratory chain-deficient parkinson disease neurons. Ann Neurol. 2016;79:66&#x2013;78. doi: 10.1002/ana.24571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24571</ArticleId><ArticleId IdType="pmc">PMC4819690</ArticleId><ArticleId IdType="pubmed">26605748</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;lle C, Fl&#xf8;nes I, Nido GS, Miletic H, Osuagwu N, Kristoffersen S, et al. Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nat Commun. 2016;7:3548. doi: 10.1038/ncomms13548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms13548</ArticleId><ArticleId IdType="pmc">PMC5121427</ArticleId><ArticleId IdType="pubmed">27874000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:05&#x2013;608. doi: 10.1038/33416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/33416</ArticleId><ArticleId IdType="pubmed">9560156</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, et al. Localization of a novel locus for autosomal recessive early-onset Parkinsonism PARK6 on human chromosome 1p35-p36. Am J Hum Genetics. 2001;68:95&#x2013;900. doi: 10.1086/319522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/319522</ArticleId><ArticleId IdType="pmc">PMC1275643</ArticleId><ArticleId IdType="pubmed">11254447</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarffe LA, Stevens DA, Dawson VL, Dawson TM. Parkin and PINK1: much more than mitophagy. Trends Neurosci. 2014;37:15&#x2013;324. doi: 10.1016/j.tins.2014.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2014.03.004</ArticleId><ArticleId IdType="pmc">PMC4075431</ArticleId><ArticleId IdType="pubmed">24735649</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak I. Mitophagy: a complex mechanism of mitochondrial removal. Antioxid Redox Sign. 2012;17:94&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pubmed">22077334</ArticleId></ArticleIdList></Reference><Reference><Citation>Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, et al. PINK1 is selectively stabilized on impaired mitochondria to activate parkin. Plos Biol. 2010;8:e1000298. doi: 10.1371/journal.pbio.1000298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1000298</ArticleId><ArticleId IdType="pmc">PMC2811155</ArticleId><ArticleId IdType="pubmed">20126261</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TM, Dawson VL. The role of parkin in familial and sporadic Parkinson&#x2019;s disease. Movement Disord. 2010;25:S32&#x2013;S39. doi: 10.1002/mds.22798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22798</ArticleId><ArticleId IdType="pmc">PMC4115293</ArticleId><ArticleId IdType="pubmed">20187240</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Liu W, Li R, Yang H. Mitophagy in Parkinson&#x2019;s disease: from pathogenesis to treatment. Cells. 2019;8:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6678174</ArticleId><ArticleId IdType="pubmed">31336937</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient Mice. J Biol Chem. 2004;279:8614&#x2013;18622. doi: 10.1074/jbc.M401135200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M401135200</ArticleId><ArticleId IdType="pubmed">14985362</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautier CA, Kitada T, Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci U S A. 2008;12:1364&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2516271</ArticleId><ArticleId IdType="pubmed">18687901</ArticleId></ArticleIdList></Reference><Reference><Citation>Morais VA, Verstreken P, Roethig A, Smet J, Snellinx A, Vanbrabant M, et al. Parkinson&#x2019;s disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. Embo Mol Med. 2009;1:9&#x2013;111. doi: 10.1002/emmm.200900006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.200900006</ArticleId><ArticleId IdType="pmc">PMC3378121</ArticleId><ArticleId IdType="pubmed">20049710</ArticleId></ArticleIdList></Reference><Reference><Citation>Peker N, Donipadi V, Sharma M, McFarlane C, Kambadur R. Loss of Parkin impairs mitochondrial function and leads to muscle atrophy. Am J Physiol. 2018;315:C164&#x2013;C185. doi: 10.1152/ajpcell.00064.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00064.2017</ArticleId><ArticleId IdType="pubmed">29561660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lill CM. Genetics of Parkinson&#x2019;s disease. Mol Cell Probe. 2016;30:86&#x2013;396. doi: 10.1016/j.mcp.2016.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcp.2016.11.001</ArticleId><ArticleId IdType="pubmed">27818248</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan BJ, Hoek S, Fon EA, Wade-Martins R. Mitochondrial dysfunction and mitophagy in Parkinson&#x2019;s: from familial to sporadic disease. Trends Biochem Sci. 2015;40:00&#x2013;10. doi: 10.1016/j.tibs.2015.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2015.02.003</ArticleId><ArticleId IdType="pubmed">25757399</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&#x2019;s disease. Nat Genet. 2014;46:89&#x2013;993. doi: 10.1038/ng.3043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3043</ArticleId><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="pubmed">25064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosal D, Ross OA, Wiley J, Irvine GB, Johnston JA, Toft M, et al. Clinical traits of LRRK2-associated Parkinson&#x2019;s disease in Ireland: A link between familial and idiopathic PD. Parkinsonism Relat D. 2005;11:49&#x2013;352. doi: 10.1016/j.parkreldis.2005.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2005.05.004</ArticleId><ArticleId IdType="pubmed">16102999</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci. 2006;9:231&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pubmed">16980962</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhardt P, Schmid B, Burbulla LF, Sch&#xf6;ndorf DC, Wagner L, Glatza M, et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell. 2013;12:54&#x2013;67. doi: 10.1016/j.stem.2013.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2013.01.008</ArticleId><ArticleId IdType="pubmed">23472874</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue M, Hinkle KM, Davies P, Trushina E, Fiesel FC, Christenson TA, et al. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis. 2015;78:72&#x2013;95. doi: 10.1016/j.nbd.2015.02.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.02.031</ArticleId><ArticleId IdType="pmc">PMC4526103</ArticleId><ArticleId IdType="pubmed">25836420</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, Maguire RS, Bennett JP, et al. Cybrids in Alzheimer&#x2019;s disease: a cellular model of the disease? Neurology. 1997;49:18&#x2013;925. doi: 10.1212/WNL.49.4.918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.49.4.918</ArticleId><ArticleId IdType="pubmed">9339668</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos D, Esteves AR, Silva DF, Janu&#xe1;rio C, Cardoso SM. The impact of mitochondrial fusion and fission modulation in sporadic Parkinson&#x2019;s disease. Mol Neurobiol. 2015;52:73&#x2013;586. doi: 10.1007/s12035-014-8893-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-8893-4</ArticleId><ArticleId IdType="pubmed">25218511</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie W, Chung KKK. Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson&#x2019;s disease. J Neurochem. 2012;122:04&#x2013;14. doi: 10.1111/j.1471-4159.2012.07775.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2012.07775.x</ArticleId><ArticleId IdType="pubmed">22537068</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham AH, Meng S, Chu QN, Chan DC. Loss of Mfn2 results in progressive retrograde degeneration of dopaminergic neurons in the nigrostriatal circuit. Hum Mol Genet. 2012;21:817&#x2013;4826. doi: 10.1093/hmg/dds311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds311</ArticleId><ArticleId IdType="pmc">PMC3607482</ArticleId><ArticleId IdType="pubmed">22859504</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Su B, Liu W, He X, Gao Y, Castellani RJ, et al. DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson&#x2019;s disease. Aging Cell. 2011;10:17&#x2013;823. doi: 10.1111/j.1474-9726.2011.00721.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2011.00721.x</ArticleId><ArticleId IdType="pmc">PMC3173562</ArticleId><ArticleId IdType="pubmed">21615675</ArticleId></ArticleIdList></Reference><Reference><Citation>Portz P, Lee MK. Changes in Drp1 function and mitochondrial morphology are associated with the &#x3b1;-synuclein pathology in a transgenic mouse model of Parkinson&#x2019;s disease. Cells. 2021;10:85. doi: 10.3390/cells10040885.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10040885</ArticleId><ArticleId IdType="pmc">PMC8070398</ArticleId><ArticleId IdType="pubmed">33924585</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM, Egami K, et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein &#x3b1;-synuclein. J Biol Chem. 2011;286:0710&#x2013;20726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121472</ArticleId><ArticleId IdType="pubmed">21489994</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, et al. Huntington disease: natural history biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10:04&#x2013;216. doi: 10.1038/nrneurol.2014.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.24</ArticleId><ArticleId IdType="pubmed">24614516</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington&#x2019;s disease chromosomes. Cell. 1993;72:71&#x2013;983. doi: 10.1016/0092-8674(93)90585-E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(93)90585-E</ArticleId><ArticleId IdType="pubmed">8458085</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos RAC. Huntington&#x2019;s disease- a clinical review. Orph J Rare Dis. 2010;5:40. doi: 10.1186/1750-1172-5-40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-5-40</ArticleId><ArticleId IdType="pmc">PMC3022767</ArticleId><ArticleId IdType="pubmed">21171977</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasir J, Floresco SB, O&#x2019;Kusky JR, Diewert VM, Richman JM, Zeisler J, et al. Targeted disruption of the Huntington&#x2019;s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 1995;81:11&#x2013;823. doi: 10.1016/0092-8674(95)90542-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(95)90542-1</ArticleId><ArticleId IdType="pubmed">7774020</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C, et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci. 2000;20:705&#x2013;3713. doi: 10.1523/JNEUROSCI.20-10-03705.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-10-03705.2000</ArticleId><ArticleId IdType="pmc">PMC6772672</ArticleId><ArticleId IdType="pubmed">10804212</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang DTW, Rintoul GL, Pandipati S, Reynolds IJ. Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol Dis. 2006;22:88&#x2013;400. doi: 10.1016/j.nbd.2005.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2005.12.007</ArticleId><ArticleId IdType="pubmed">16473015</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington&#x2019;s disease. Neurobiol Dis. 2008;31:1&#x2013;88. doi: 10.1016/j.nbd.2008.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.03.010</ArticleId><ArticleId IdType="pmc">PMC2528878</ArticleId><ArticleId IdType="pubmed">18502655</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintanilla RA, Jin YN, von Bernhardi R, Johnson GV. Mitochondrial permeability transition pore induces mitochondria injury in Huntington disease. Mol Neurodegener. 2013;8:5&#x2013;45. doi: 10.1186/1750-1326-8-45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-45</ArticleId><ArticleId IdType="pmc">PMC3878840</ArticleId><ArticleId IdType="pubmed">24330821</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan MMY, Raymond LA. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington&#x2019;s disease. Prog Neurobiol. 2007;81:72&#x2013;93. doi: 10.1016/j.pneurobio.2006.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2006.11.003</ArticleId><ArticleId IdType="pubmed">17188796</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya Y, et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington&#x2019;s disease. Neuron. 2005;47:9&#x2013;41. doi: 10.1016/j.neuron.2005.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.06.005</ArticleId><ArticleId IdType="pubmed">15996546</ArticleId></ArticleIdList></Reference><Reference><Citation>Milakovic T, Quintanilla RA, Johnson GVW. Mutant Huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells. J Biol Chem. 2006;281:4785&#x2013;34795. doi: 10.1074/jbc.M603845200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M603845200</ArticleId><ArticleId IdType="pubmed">16973623</ArticleId></ArticleIdList></Reference><Reference><Citation>Choo YS, Johnson GVW, MacDonald M, Detloff PJ, Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet. 2004;13:407&#x2013;1420. doi: 10.1093/hmg/ddh162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddh162</ArticleId><ArticleId IdType="pubmed">15163634</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, et al. Mitochondrial loss dysfunction and altered dynamics in Huntington&#x2019;s disease. Hum Mol Genet. 2010;19:919&#x2013;3935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947400</ArticleId><ArticleId IdType="pubmed">20660112</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA, et al. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington&#x2019;s disease: implications for selective neuronal damage. Hum Mol Genet. 2011;20:438&#x2013;1455. doi: 10.1093/hmg/ddr024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr024</ArticleId><ArticleId IdType="pmc">PMC3049363</ArticleId><ArticleId IdType="pubmed">21257639</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Sun X, Qi X. Inhibition of Drp1 hyperactivation reduces neuropathology and behavioral deficits in zQ175 knock-in mouse model of Huntington&#x2019;s disease. Biochem Bioph Res. 2018;507:19&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6299831</ArticleId><ArticleId IdType="pubmed">30449600</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr AL, Li S, Wang CE, Li H, Wang J, Rong J, et al. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci. 2008;28:783&#x2013;2792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2652473</ArticleId><ArticleId IdType="pubmed">18337408</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouillet E, Guyot M, Mittoux V, Altairac S, Cond&#xe9; F, Palfi S, et al. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J Neurochem. 1998;70:94&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">9453576</ArticleId></ArticleIdList></Reference><Reference><Citation>Benchoua A, Trioulier Y, Zala D, Gaillard MC, Lefort N, Dufour N, et al. Involvement of Mitochondrial Complex II defects in neuronal death produced by N-terminus fragment of mutated Huntingtin. Mol Biol Cell. 2006;17:652&#x2013;1663. doi: 10.1091/mbc.e05-07-0607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e05-07-0607</ArticleId><ArticleId IdType="pmc">PMC1415305</ArticleId><ArticleId IdType="pubmed">16452635</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan WA, Bird ED, Aprille JR. Regional mitochondrial respiratory activity in Huntington&#x2019;s disease brain. J Neurochem. 1985;44:948&#x2013;1950. doi: 10.1111/j.1471-4159.1985.tb07192.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1985.tb07192.x</ArticleId><ArticleId IdType="pubmed">2985766</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AHV. Mitochondrial defect in Huntington&#x2019;s disease caudate nucleus. Ann Neurol. 1996;39:85&#x2013;389. doi: 10.1002/ana.410390317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410390317</ArticleId><ArticleId IdType="pubmed">8602759</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne SE, Bowling AC, Macgarvey U, Baik MJ, Berger SC, Muquit MMK, et al. Oxidative damage and metabolic dysfunction in Huntington&#x2019;s disease: selective vulnerability of the basal ganglia. Ann Neurol. 1997;41:46&#x2013;653. doi: 10.1002/ana.410410514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410514</ArticleId><ArticleId IdType="pubmed">9153527</ArticleId></ArticleIdList></Reference><Reference><Citation>Borasio GD, Miller RG. Clinical characteristics and management of ALS. Semin Neuros. 2001;21:55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11442324</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott EO, Malek AM, Lacomis D. Chapter 13 The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol. 2016;138:25&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Gonzalez de Aguilar JL, Oudart H, de Tapia M, Barbeito L, Loeffler JP. Mitochondria in amyotrophic lateral sclerosis: a trigger and a target. Neurodegener Dis. 2004;1:45&#x2013;254. doi: 10.1159/000085063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000085063</ArticleId><ArticleId IdType="pubmed">16908975</ArticleId></ArticleIdList></Reference><Reference><Citation>Moller A, Bauer CS, Cohen RN, Webster CP, Vos KJD. Amyotrophic lateral sclerosis-associated mutant SOD1 inhibits anterograde axonal transport of mitochondria by reducing Miro1 levels. Hum Mol Genet. 2017;26:668&#x2013;4679. doi: 10.1093/hmg/ddx348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx348</ArticleId><ArticleId IdType="pmc">PMC5886184</ArticleId><ArticleId IdType="pubmed">28973175</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos KJD, Chapman AL, Tennant ME, Manser C, Tudor EL, Lau KF, et al. Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum Mol Genet. 2007;16:720&#x2013;2728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516806</ArticleId><ArticleId IdType="pubmed">17725983</ArticleId></ArticleIdList></Reference><Reference><Citation>Magran&#xe9; J, Cortez C, Gan WB, Manfredi G. Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum Mol Genet. 2014;23:413&#x2013;1424. doi: 10.1093/hmg/ddt528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt528</ArticleId><ArticleId IdType="pmc">PMC3929084</ArticleId><ArticleId IdType="pubmed">24154542</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta AR, Gregory JM, Dando O, Carter RN, Burr K, Nanda J, et al. Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis. Acta Neuropathol. 2021;141:57&#x2013;279. doi: 10.1007/s00401-020-02252-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02252-5</ArticleId><ArticleId IdType="pmc">PMC7847443</ArticleId><ArticleId IdType="pubmed">33398403</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller FL, Liu Y, Jernigan A, Borchelt D, Richardson A, Remmen HV. MnSOD deficiency has a differential effect on disease progression in two different ALS mutant mouse models. Muscle Nerve. 2008;38:173&#x2013;1183. doi: 10.1002/mus.21049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21049</ArticleId><ArticleId IdType="pubmed">18720509</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagaraj CJ, Parakh S, Atkin JD. Emerging evidence highlighting the importance of redox dysregulation in the pathogenesis of amyotrophic lateral sclerosis (ALS) Front Cell Neurosci. 2021;14:81950. doi: 10.3389/fncel.2020.581950.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.581950</ArticleId><ArticleId IdType="pmc">PMC7929997</ArticleId><ArticleId IdType="pubmed">33679322</ArticleId></ArticleIdList></Reference><Reference><Citation>Velde CV, McDonald KK, Boukhedimi Y, McAlonis-Downes M, Lobsiger CS, Hadj SB, et al. Misfolded SOD1 associated with motor neuron mitochondria alters mitochondrial shape and distribution prior to clinical onset. PLoS ONE. 2011;6:e22031. doi: 10.1371/journal.pone.0022031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0022031</ArticleId><ArticleId IdType="pmc">PMC3136936</ArticleId><ArticleId IdType="pubmed">21779368</ArticleId></ArticleIdList></Reference><Reference><Citation>Magran&#xe9; J, Hervias I, Henning MS, Damiano M, Kawamata H, Manfredi G. Mutant SOD1 in neuronal mitochondria causes toxicity and mitochondrial dynamics abnormalities. Hum Mol Genet. 2009;18:552&#x2013;4564. doi: 10.1093/hmg/ddp421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp421</ArticleId><ArticleId IdType="pmc">PMC2773270</ArticleId><ArticleId IdType="pubmed">19779023</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Song Y, Kincaid B, Bossy B, Bossy-Wetzel E. Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: Neuroprotection by SIRT3 and PGC-1&#x3b1;. Neurobiol Dis. 2013;51:2&#x2013;81. doi: 10.1016/j.nbd.2012.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.07.004</ArticleId><ArticleId IdType="pmc">PMC3992938</ArticleId><ArticleId IdType="pubmed">22819776</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo G, Yi J, Ma C, Xiao Y, Yi F, Yu T, et al. Defective mitochondrial dynamics is an early event in skeletal muscle of an amyotrophic lateral sclerosis mouse model. PLoS ONE. 2013;8:e82112. doi: 10.1371/journal.pone.0082112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0082112</ArticleId><ArticleId IdType="pmc">PMC3855744</ArticleId><ArticleId IdType="pubmed">24324755</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Z, Wang W, Perry G, Zhu X, Wang X. Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis. Transl Neurodegener. 2015;4:4. doi: 10.1186/s40035-015-0037-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-015-0037-x</ArticleId><ArticleId IdType="pmc">PMC4518588</ArticleId><ArticleId IdType="pubmed">26225210</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, Iwata M. Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2007;66:1&#x2013;16. doi: 10.1097/nen.0b013e31802d9000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e31802d9000</ArticleId><ArticleId IdType="pubmed">17204932</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan W, Naniche N, Bogush A, Pedrini S, Trotti D, Pasinelli P. Small peptides against the mutant SOD1/Bcl-2 toxic mitochondrial complex restore mitochondrial function and cell viability in mutant SOD1-mediated ALS. J Neurosci. 2013;33:1588&#x2013;11598. doi: 10.1523/JNEUROSCI.5385-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5385-12.2013</ArticleId><ArticleId IdType="pmc">PMC3724557</ArticleId><ArticleId IdType="pubmed">23843527</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattiazzi M, D&#x2019;Aurelio M, Gajewski CD, Martushova K, Kiaei M, Beal MF, et al. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem. 2002;277:9626&#x2013;29633. doi: 10.1074/jbc.M203065200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M203065200</ArticleId><ArticleId IdType="pubmed">12050154</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Li A, Li X, Yi J. Dysregulated mitochondrial Ca2+ and ROS signaling in skeletal muscle of ALS mouse model. Arch Biochem Biophys. 2019;663:49&#x2013;258. doi: 10.1016/j.abb.2019.01.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2019.01.024</ArticleId><ArticleId IdType="pmc">PMC6506190</ArticleId><ArticleId IdType="pubmed">30682329</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Li L, Lin WL, Dickson DW, Petrucelli L, Zhang T, et al. The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Hum Mol Genet. 2013;22:706&#x2013;4719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820133</ArticleId><ArticleId IdType="pubmed">23827948</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Pan LH, Watanabe M, Kato T, Itoyama Y. Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci Lett. 1995;199:52&#x2013;154. doi: 10.1016/0304-3940(95)12039-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(95)12039-7</ArticleId><ArticleId IdType="pubmed">8584246</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Pan LH, Watanabe M, Konno H, Kato T, Itoyama Y. Upregulation of protein-tyrosine nitration in the anterior horn cells of amyotrophic lateral sclerosis. Neurol Res. 1997;19:24&#x2013;128. doi: 10.1080/01616412.1997.11740784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01616412.1997.11740784</ArticleId><ArticleId IdType="pubmed">9175139</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemerkov&#xe1; P, Vali&#x161; M. Role of oxidative stress in the pathogenesis of amyotrophic lateral sclerosis: antioxidant metalloenzymes and therapeutic strategies. Biomolecule. 2021;11:37. doi: 10.3390/biom11030437.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11030437</ArticleId><ArticleId IdType="pmc">PMC8002298</ArticleId><ArticleId IdType="pubmed">33809730</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri A, Fiorenzo P, Nencini M, Cozzolino M, Pesaresi MG, Valle C, et al. Glutaredoxin 2 prevents aggregation of mutant SOD1 in mitochondria and abolishes its toxicity. Hum Mol Genet. 2010;19:529&#x2013;4542. doi: 10.1093/hmg/ddq383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq383</ArticleId><ArticleId IdType="pmc">PMC3298854</ArticleId><ArticleId IdType="pubmed">20829229</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer&#x2019;s pathology in female mouse model of Alzheimer&#x2019;s disease. Proc National Acad Sci U S A. 2009;106:4670&#x2013;14675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732886</ArticleId><ArticleId IdType="pubmed">19667196</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyo P, del Garc&#xed;a-Redondo A, Bustos F, de Molina JA, Sayed Y, Alonso-Navarro H, Caballero L, Arenas J, et al. Oxidative stress in skin fibroblasts cultures of patients with Huntington&#x2019;s disease. Neurochem Res. 2006;31:103&#x2013;1109. doi: 10.1007/s11064-005-9236-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-005-9236-7</ArticleId><ArticleId IdType="pubmed">16944322</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:61&#x2013;872. doi: 10.1016/j.cell.2007.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.11.019</ArticleId><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Zheng X, Ansari Z, Bunnell MC, Herdy JR, Traxler L, et al. Mitochondrial aging defects emerge in directly reprogrammed human neurons due to their metabolic profile. Cell Rep. 2018;23:550&#x2013;2558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6478017</ArticleId><ArticleId IdType="pubmed">29847787</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinrich C, Bergami M, Gasc&#xf3;n S, Lepier A, Vigan&#xf2; F, Dimou L, et al. Sox2-mediated conversion of NG2 glia into induced neurons in the injured adult cerebral cortex. Stem Cell Rep. 2014;3:000&#x2013;1014. doi: 10.1016/j.stemcr.2014.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2014.10.007</ArticleId><ArticleId IdType="pmc">PMC4264057</ArticleId><ArticleId IdType="pubmed">25458895</ArticleId></ArticleIdList></Reference><Reference><Citation>Victor MB, Richner M, Olsen HE, Lee SW, Monteys AM, Ma C, et al. Striatal neurons directly converted from Huntington&#x2019;s disease patient fibroblasts recapitulate age-associated disease phenotypes. Nat Neurosci. 2018;21:41&#x2013;352. doi: 10.1038/s41593-018-0075-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0075-7</ArticleId><ArticleId IdType="pmc">PMC5857213</ArticleId><ArticleId IdType="pubmed">29403030</ArticleId></ArticleIdList></Reference><Reference><Citation>Victor MB, Richner M, Olsen HE, Lee SW, Monteys AM, Ma C, et al. Author Correction: Striatal neurons directly converted from Huntington&#x2019;s disease patient fibroblasts recapitulate age-associated disease phenotypes. Nat Neurosci. 2020;23:307&#x2013;1307. doi: 10.1038/s41593-020-00714-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00714-3</ArticleId><ArticleId IdType="pubmed">32879483</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov. 2017;16:15&#x2013;130. doi: 10.1038/nrd.2016.274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2016.274</ArticleId><ArticleId IdType="pmc">PMC6416143</ArticleId><ArticleId IdType="pubmed">27980341</ArticleId></ArticleIdList></Reference><Reference><Citation>Payne NL, Sylvain A, O&#x2019;Brien C, Herszfeld D, Sun G, Bernard CCA. Application of human induced pluripotent stem cells for modeling and treating neurodegenerative diseases. New Biotechnol. 2015;32:12&#x2013;228. doi: 10.1016/j.nbt.2014.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbt.2014.05.001</ArticleId><ArticleId IdType="pubmed">24815224</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman SA, Nedergaard M, Windrem MS. Glial progenitor cell&#x2013;based treatment and modeling of neurological disease. Science. 2012;338:91&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3548656</ArticleId><ArticleId IdType="pubmed">23112326</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008;29:169&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">18669821</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Hu D, Shang Y, Qi X. Using induced pluripotent stem cell neuronal models to study neurodegenerative diseases. Biochim Biophys Acta Mol Basis Dis. 2019;1866:65431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6751032</ArticleId><ArticleId IdType="pubmed">30898538</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones VC, Atkinson-Dell R, Verkhratsky A, Mohamet L. Aberrant iPSC-derived human astrocytes in Alzheimer&#x2019;s disease. Cell Death Dis. 2017;8:e2696&#x2013;e2696. doi: 10.1038/cddis.2017.89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2017.89</ArticleId><ArticleId IdType="pmc">PMC5386580</ArticleId><ArticleId IdType="pubmed">28333144</ArticleId></ArticleIdList></Reference><Reference><Citation>Penney J, Ralvenius WT, Tsai LH. Modeling Alzheimer&#x2019;s disease with iPSC-derived brain cells. Mol Psychiatr. 2019;25:48&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6906186</ArticleId><ArticleId IdType="pubmed">31391546</ArticleId></ArticleIdList></Reference><Reference><Citation>Trombetta-Lima M, Sabogal-Gu&#xe1;queta AM, Dolga AM. Mitochondrial dysfunction in neurodegenerative diseases: a focus on iPSC-derived neuronal models. Cell Calcium. 2021;94:02362. doi: 10.1016/j.ceca.2021.102362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2021.102362</ArticleId><ArticleId IdType="pubmed">33540322</ArticleId></ArticleIdList></Reference><Reference><Citation>Arber C, Lovejoy C, Wray S. Stem cell models of Alzheimer&#x2019;s disease: progress and challenges. Alzheimer&#x2019;s Res Ther. 2017;9:2. doi: 10.1186/s13195-016-0228-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-016-0228-4</ArticleId><ArticleId IdType="pmc">PMC5470327</ArticleId><ArticleId IdType="pubmed">28610595</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T. Modeling familial Alzheimer&#x2019;s disease with induced pluripotent stem cells. Hum Mol Genet. 2011;20:530&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">21900357</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproul AA, Jacob S, Pre D, Kim SH, Nestor MW, Navarro-Sobrino M, et al. Characterization and molecular profiling of PSEN1 familial Alzheimer&#x2019;s disease iPSC-derived neural progenitors. PLoS ONE. 2014;9:e84547. doi: 10.1371/journal.pone.0084547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0084547</ArticleId><ArticleId IdType="pmc">PMC3885572</ArticleId><ArticleId IdType="pubmed">24416243</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, et al. Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells. Nature. 2012;482:16&#x2013;220. doi: 10.1038/nature10821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10821</ArticleId><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A, Zhi L, Zhang H. LRRK2 and mitochondria: recent advances and current views. Brain Res. 2019;1702:6&#x2013;104. doi: 10.1016/j.brainres.2018.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.06.010</ArticleId><ArticleId IdType="pmc">PMC6281802</ArticleId><ArticleId IdType="pubmed">29894679</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ndorf DC, Ivanyuk D, Baden P, Sanchez-Martinez A, Cicco SD, Yu C, et al. The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson&#x2019;s disease. Cell Rep. 2018;23:976&#x2013;2988. doi: 10.1016/j.celrep.2018.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.05.009</ArticleId><ArticleId IdType="pubmed">29874584</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng X, Couture LA. Pluripotent stem cells for Parkinson&#x2019;s disease: progress and challenges. Stem Cell Res Ther. 2013;4:5. doi: 10.1186/scrt173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/scrt173</ArticleId><ArticleId IdType="pmc">PMC3707048</ArticleId><ArticleId IdType="pubmed">23672848</ArticleId></ArticleIdList></Reference><Reference><Citation>Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, et al. Disease-specific induced pluripotent stem cells. Cell. 2008;134:77&#x2013;886. doi: 10.1016/j.cell.2008.07.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.07.041</ArticleId><ArticleId IdType="pmc">PMC2633781</ArticleId><ArticleId IdType="pubmed">18691744</ArticleId></ArticleIdList></Reference><Reference><Citation>Camnasio S, Carri AD, Lombardo A, Grad I, Mariotti C, Castucci A, et al. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington&#x2019;s disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol Dis. 2012;46:1&#x2013;51. doi: 10.1016/j.nbd.2011.12.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.12.042</ArticleId><ArticleId IdType="pubmed">22405424</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N, An MC, Montoro D, Ellerby LM. Characterization of human Huntington&#x2019;s disease cell model from induced pluripotent stem cells. PLoS Curr. 2010;2:RRN1193. doi: 10.1371/currents.RRN1193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/currents.RRN1193</ArticleId><ArticleId IdType="pmc">PMC2966296</ArticleId><ArticleId IdType="pubmed">21037797</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattis VB, Tom C, Akimov S, Saeedian J, &#xd8;stergaard ME, Southwell AL, Doty CN, Ornelas L, Sahabian A, Lenaeus L, et al. HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Hum Mol Genet. 2015;24:257&#x2013;3271. doi: 10.1093/hmg/ddv080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv080</ArticleId><ArticleId IdType="pmc">PMC4424959</ArticleId><ArticleId IdType="pubmed">25740845</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes C, Tang Y, Anjo SI, Manadas B, Onofre I, Almeida LP, et al. Mitochondrial and redox modifications in huntington disease induced pluripotent stem cells rescued by CRISPR/Cas9 CAGs targeting. Front Cell Dev Biol. 2020;8:76592. doi: 10.3389/fcell.2020.576592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.576592</ArticleId><ArticleId IdType="pmc">PMC7536317</ArticleId><ArticleId IdType="pubmed">33072759</ArticleId></ArticleIdList></Reference><Reference><Citation>HD iPSC Consortium Bioenergetic deficits in Huntington&#x2019;s disease iPSC-derived neural cells and rescue with glycolytic metabolites. Hum Mol Genet. 2020;29:757&#x2013;1771. doi: 10.1093/hmg/ddy430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy430</ArticleId><ArticleId IdType="pmc">PMC7372552</ArticleId><ArticleId IdType="pubmed">30768179</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoroso MW, Croft GF, Williams DJ, O&#x2019;Keeffe S, Carrasco MA, Davis AR, et al. Accelerated high-yield generation of limb-innervating motor neurons from human stem cells. J Neurosci. 2013;33:74&#x2013;86. doi: 10.1523/JNEUROSCI.0906-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0906-12.2013</ArticleId><ArticleId IdType="pmc">PMC3711539</ArticleId><ArticleId IdType="pubmed">23303937</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu Q, Li D, Louis KR, Li X, Yang H, Sun Q, et al. High-efficiency motor neuron differentiation from human pluripotent stem cells and the function of Islet-1. Nat Commun. 2014;5:449.</Citation><ArticleIdList><ArticleId IdType="pubmed">24622388</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Qian K, Du Z, Cao J, Petersen A, Liu H, et al. Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. Cell Stem Cell. 2014;14:96&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4230530</ArticleId><ArticleId IdType="pubmed">24704493</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008;321:218&#x2013;1221. doi: 10.1126/science.1158799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1158799</ArticleId><ArticleId IdType="pubmed">18669821</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebert AD, Yu J, Rose FF, Mattis VB, Lorson CL, Thomson JA, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature. 2008;457:77&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659408</ArticleId><ArticleId IdType="pubmed">19098894</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilican B, Serio A, Barmada SJ, Nishimura AL, Sullivan GJ, Carrasco M, et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A. 2012;109:803&#x2013;808. doi: 10.1073/pnas.1202922109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1202922109</ArticleId><ArticleId IdType="pmc">PMC3326463</ArticleId><ArticleId IdType="pubmed">22451909</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen SP, Rajan S, Duffy L, Mortiboys H, Higginbottom A, Grierson AJ, et al. Superoxide dismutase 1 mutation in a cellular model of amyotrophic lateral sclerosis shifts energy generation from oxidative phosphorylation to glycolysis. Neurobiol Aging. 2014;35:499&#x2013;1509. doi: 10.1016/j.neurobiolaging.2013.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.11.025</ArticleId><ArticleId IdType="pubmed">24439480</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdullah AI, Pollock A, Sun T. The path from skin to brain: generation of functional neurons from fibroblasts. Mol Neurobiol. 2012;45:86&#x2013;595. doi: 10.1007/s12035-012-8277-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-012-8277-6</ArticleId><ArticleId IdType="pmc">PMC3564239</ArticleId><ArticleId IdType="pubmed">22614130</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Ren Y, Yuen EY, Zhong P, Ghaedi M, Hu Z, et al. Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nat Commun. 2012;7:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498452</ArticleId><ArticleId IdType="pubmed">22314364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Ren Y, Yuen EY, Zhong P, Ghaedi M, Hu Z, et al. Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nat Commun. 2012;3:68. doi: 10.1038/ncomms1669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms1669</ArticleId><ArticleId IdType="pmc">PMC3498452</ArticleId><ArticleId IdType="pubmed">22314364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma T, Xie M, Laurent T, Ding S. Progress in the reprogramming of somatic cells. Circ Res. 2013;112:62&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3790469</ArticleId><ArticleId IdType="pubmed">23371904</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Du Y, Deng H. Direct Lineage reprogramming: strategies mechanisms and applications. Cell Stem Cell. 2015;16:19&#x2013;134. doi: 10.1016/j.stem.2015.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2015.01.013</ArticleId><ArticleId IdType="pubmed">25658369</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J, Marchetto MC, Bardy C, Gage FH. Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience. Nat Rev Neurosci. 2016;17:24&#x2013;37. doi: 10.1038/nrn.2016.46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.46</ArticleId><ArticleId IdType="pmc">PMC6276815</ArticleId><ArticleId IdType="pubmed">27194476</ArticleId></ArticleIdList></Reference><Reference><Citation>Htike TT, Mishra S, Kumar S, Padmanabhan P, Guly&#xe1;s B. Peripheral biomarkers for early detection of Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Mol Neurobiol. 2019;56:256&#x2013;2277. doi: 10.1007/s12035-018-1151-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1151-4</ArticleId><ArticleId IdType="pubmed">30008073</ArticleId></ArticleIdList></Reference><Reference><Citation>Riancho J, Arozamena S, Muna&#xed;n AL. de Dermic-derived fibroblasts for the study of amyotrophic lateral sclerosis. Neural Regen Res. 2020;15:043. doi: 10.4103/1673-5374.282257.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.282257</ArticleId><ArticleId IdType="pmc">PMC7716046</ArticleId><ArticleId IdType="pubmed">32394958</ArticleId></ArticleIdList></Reference><Reference><Citation>McAnulty RJ. Fibroblasts and myofibroblasts: Their source, function and role in disease. Int J Biochem Cell Biol. 2007;39:66&#x2013;671. doi: 10.1016/j.biocel.2006.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2006.11.005</ArticleId><ArticleId IdType="pubmed">17196874</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBleu VS, Neilson EG. Origin and functional heterogeneity of fibroblasts. Faseb J. 2020;34:519&#x2013;3536. doi: 10.1096/fj.201903188R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201903188R</ArticleId><ArticleId IdType="pubmed">32037627</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracy LE, Minasian RA, Caterson EJ. Extracellular matrix and dermal fibroblast function in the healing wound. Adv Wound Care. 2016;5:19&#x2013;136. doi: 10.1089/wound.2014.0561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/wound.2014.0561</ArticleId><ArticleId IdType="pmc">PMC4779293</ArticleId><ArticleId IdType="pubmed">26989578</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Su S, Zhou S, Yang W, Deng X, Sun Y, et al. How to reprogram human fibroblasts to neurons. Cell Biosci. 2020;10:16. doi: 10.1186/s13578-020-0377-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13578-020-0377-9</ArticleId><ArticleId IdType="pmc">PMC7549215</ArticleId><ArticleId IdType="pubmed">33062254</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W, Qiu B, Guan W, Wang Q, Wang M, Li W, et al. Direct conversion of normal and Alzheimer&#x2019;s disease human fibroblasts into neuronal cells by small molecules. Cell Stem Cell. 2015;17:04&#x2013;212. doi: 10.1016/j.stem.2015.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2015.07.006</ArticleId><ArticleId IdType="pubmed">26253202</ArticleId></ArticleIdList></Reference><Reference><Citation>Han DW, Tapia N, Hermann A, Hemmer K, H&#xf6;ing S, Ara&#xfa;zo-Bravo MJ, et al. Direct reprogramming of fibroblasts into neural stem cells by defined factors. Cell Stem Cell. 2012;10:65&#x2013;472. doi: 10.1016/j.stem.2012.02.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2012.02.021</ArticleId><ArticleId IdType="pubmed">22445517</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Wang Y, He Z, Yang H, Gao WQ. Direct conversion of mouse fibroblasts to GABAergic neurons with combined medium without the introduction of transcription factors or miRNAs. Cell Cycle. 2015;14:451&#x2013;2460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4615089</ArticleId><ArticleId IdType="pubmed">26114472</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Chu X, Jiang H, Schilling H, Chen S, Feng J. Induced dopaminergic neurons: a new promise for Parkinson&#x2019;s disease. Redox Biol. 2017;11:06&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5256671</ArticleId><ArticleId IdType="pubmed">28110217</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbulla LF, Krainc D. The role of dopamine in the pathogenesis of GBA1-linked Parkinson&#x2019;s disease. Neurobiol Dis. 2019;132:04545. doi: 10.1016/j.nbd.2019.104545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104545</ArticleId><ArticleId IdType="pmc">PMC6834905</ArticleId><ArticleId IdType="pubmed">31351996</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannetti EA, Fuhrmann M. Unsupervised excitation: GABAergic dysfunctions in Alzheimer&#x2019;s disease. Brain Res. 2018;1707:16&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">30503351</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosie KA, King AE, Blizzard CA, Vickers JC, Dickson TC. Chronic excitotoxin-induced axon degeneration in a compartmented neuronal culture model. ASN Neuro. 2012;4:e00076. doi: 10.1042/AN20110031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/AN20110031</ArticleId><ArticleId IdType="pmc">PMC3284768</ArticleId><ArticleId IdType="pubmed">22356284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang N, Ng YH, Pang ZP, S&#xfc;dhof TC, Wernig M. Induced neuronal cells: how to make and define a neuron. Cell Stem Cell. 2011;9:17&#x2013;25. doi: 10.1016/j.stem.2011.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2011.06.007</ArticleId><ArticleId IdType="pmc">PMC4377331</ArticleId><ArticleId IdType="pubmed">22136927</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfisterer U, Ek F, Lang S, Soneji S, Olsson R, Parmar M. Small molecules increase direct neural conversion of human fibroblasts. Sci Rep. 2016;6:8290. doi: 10.1038/srep38290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep38290</ArticleId><ArticleId IdType="pmc">PMC5137010</ArticleId><ArticleId IdType="pubmed">27917895</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Cao H, Guo S, Zhu H, Tao H, Zhang L, et al. Small molecular compounds efficiently convert human fibroblasts directly into neurons. Mol Med Rep. 2020;22:763&#x2013;4771. doi: 10.3892/mmr.2020.11148.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2020.11148</ArticleId><ArticleId IdType="pmc">PMC7646904</ArticleId><ArticleId IdType="pubmed">33174059</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai P, Harada Y, Takamatsu T. Highly efficient direct conversion of human fibroblasts to neuronal cells by chemical compounds. J Clin Biochem Nutr. 2015;56:66&#x2013;170. doi: 10.3164/jcbn.15-39.</Citation><ArticleIdList><ArticleId IdType="doi">10.3164/jcbn.15-39</ArticleId><ArticleId IdType="pmc">PMC4454078</ArticleId><ArticleId IdType="pubmed">26060345</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Lee HY, Lee BE, Gerovska D, Park SY, Zaehres H, et al. Sequentially induced motor neurons from human fibroblasts facilitate locomotor recovery in a rodent spinal cord injury model. Elife. 2020;9:e52069. doi: 10.7554/eLife.52069.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.52069</ArticleId><ArticleId IdType="pmc">PMC7311175</ArticleId><ArticleId IdType="pubmed">32571478</ArticleId></ArticleIdList></Reference><Reference><Citation>Clos AL, Kayed R, Lasagna-Reeves CA. Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis. Front Neurol. 2012;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262151</ArticleId><ArticleId IdType="pubmed">22319507</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler MJ, Coronel C, Shelton E, Seegmiller JE, Dewji NN. Increased gene expression of Alzheimer disease beta-amyloid precursor protein in senescent cultured fibroblasts. Proc National Acad Sci U S A. 1991;88:6&#x2013;20. doi: 10.1073/pnas.88.1.6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.1.6</ArticleId><ArticleId IdType="pmc">PMC50738</ArticleId><ArticleId IdType="pubmed">1702541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kann O, Kov&#xe1;cs R. Mitochondria and neuronal activity. Am J Physiol. 2007;292:C641&#x2013;C657. doi: 10.1152/ajpcell.00222.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00222.2006</ArticleId><ArticleId IdType="pubmed">17092996</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajasingh S, Isai DG, Samanta S, Zhou ZG, Dawn B, Kinsey WH, et al. Manipulation-free cultures of human iPSC-derived cardiomyocytes offer a novel screening method for cardiotoxicity. Acta Pharmacol Sin. 2018;39:590&#x2013;1603. doi: 10.1038/aps.2017.183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aps.2017.183</ArticleId><ArticleId IdType="pmc">PMC6289337</ArticleId><ArticleId IdType="pubmed">29620051</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikuchi T, Morizane A, Doi D, Magotani H, Onoe H, Hayashi T, et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson&#x2019;s disease model. Nature. 2017;548:92&#x2013;596. doi: 10.1038/nature23664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23664</ArticleId><ArticleId IdType="pubmed">28858313</ArticleId></ArticleIdList></Reference><Reference><Citation>Jr WDP, Parks J, Filley CM, Kleinschmidt-DeMasters BK. Electron transport chain defects in Alzheimer&#x2019;s disease brain. Neurology. 1994;44:1090&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8208407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kish SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang L, et al. Brain cytochrome oxidase in Alzheimer&#x2019;s disease. J Neurochem. 1992;59:76&#x2013;779. doi: 10.1111/j.1471-4159.1992.tb09439.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1992.tb09439.x</ArticleId><ArticleId IdType="pubmed">1321237</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender A, Desplats P, Spencer B, Rockenstein E, Adame A, Elstner M, et al. TOM40 mediates mitochondrial dysfunction induced by &#x3b1;-synuclein accumulation in Parkinson&#x2019;s disease. PLoS ONE. 2013;8:e62277. doi: 10.1371/journal.pone.0062277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0062277</ArticleId><ArticleId IdType="pmc">PMC3633917</ArticleId><ArticleId IdType="pubmed">23626796</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Z, Liu F, Liu C, Jin B, Jiang Y, Tang M, et al. Mutant huntingtin inhibits the mitochondrial unfolded protein response by impairing ABCB10 mRNA stability. Biochim Biophys Acta Bba Mol Basis Dis. 2019;1865:428&#x2013;1435. doi: 10.1016/j.bbadis.2018.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2018.11.013</ArticleId><ArticleId IdType="pmc">PMC6502650</ArticleId><ArticleId IdType="pubmed">30802639</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyo P, del Garc&#xed;a-Redondo A, Bustos F, de Molina JA, Sayed Y, Alonso-Navarro H, Caballero L, et al. Oxidative stress in skin fibroblasts cultures from patients with Parkinson&#x2019;s disease. BMC Neurol. 2010;10:5. doi: 10.1186/1471-2377-10-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-10-5</ArticleId><ArticleId IdType="pmc">PMC2976734</ArticleId><ArticleId IdType="pubmed">20958999</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Casacuberta I, Ju&#xe1;rez-Flores DL, Ezquerra M, Fucho R, Catal&#xe1;n-Garc&#xed;a M, Guitart-Mampel M, et al. Mitochondrial and autophagic alterations in skin fibroblasts from Parkinson disease patients with Parkin mutations. Aging. 2019;9:750&#x2013;3767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6594812</ArticleId><ArticleId IdType="pubmed">31180333</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell SM, Barnes K, Clemmens H, Al-Rafiah AR, Al-ofi EA, Leech V, et al. Ursodeoxycholic Acid Improves Mitochondrial function and redistributes Drp1 in fibroblasts from patients with either sporadic or familial Alzheimer&#x2019;s disease. J Mol Biol. 2018;430:942&#x2013;3953. doi: 10.1016/j.jmb.2018.08.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2018.08.019</ArticleId><ArticleId IdType="pmc">PMC6193139</ArticleId><ArticleId IdType="pubmed">30171839</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilocchi M, Colugnat I, Lualdi M, Meduri M, Marini F, Carregari VC, et al. Exploring the impact of PARK2 mutations on the total and mitochondrial proteome of human skin fibroblasts. Front Cell Dev Biol. 2020;8:23. doi: 10.3389/fcell.2020.00423.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.00423</ArticleId><ArticleId IdType="pmc">PMC7300190</ArticleId><ArticleId IdType="pubmed">32596240</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillery O, Malka F, Frachon P, Milea D, Rojo M, Lomb&#xe8;s A. Modulation of mitochondrial morphology by bioenergetics defects in primary human fibroblasts. Neuromuscul Disord. 2008;18:19&#x2013;330. doi: 10.1016/j.nmd.2007.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2007.12.008</ArticleId><ArticleId IdType="pubmed">18395446</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin J, Reiman EM, Beach TG, Serrano GE, Sabbagh MN, Nielsen M, et al. Effect of ApoE isoforms on mitochondria in Alzheimer disease. Neurology. 2020;94:e2404&#x2013;e2411. doi: 10.1212/WNL.0000000000009582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009582</ArticleId><ArticleId IdType="pmc">PMC7455369</ArticleId><ArticleId IdType="pubmed">32457210</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Liu C, Parker WD, Chen H, Beach TG, Liu X, et al. Mitochondrial DNA rearrangement spectrum in brain tissue of Alzheimer&#x2019;s disease: analysis of 13 cases. PLoS ONE. 2016;11:e0154582. doi: 10.1371/journal.pone.0154582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0154582</ArticleId><ArticleId IdType="pmc">PMC4907522</ArticleId><ArticleId IdType="pubmed">27299301</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims NR, Finegan JM, Blass JP, Bowen DM, Neary D. Mitochondrial function in brain tissue in primary degenerative dementia. Brain Res. 1987;436:1&#x2013;38. doi: 10.1016/0006-8993(87)91553-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(87)91553-8</ArticleId><ArticleId IdType="pubmed">3690351</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek SH, Park SJ, Jeong JI, Kim SH, Han J, Kyung JW, et al. Inhibition of Drp1 ameliorates synaptic depression, A&#x3b2; deposition and cognitive impairment in an Alzheimer&#x2019;s disease model. J Neurosci. 2017;37:099&#x2013;5110. doi: 10.1523/JNEUROSCI.2385-16.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2385-16.2017</ArticleId><ArticleId IdType="pmc">PMC6596467</ArticleId><ArticleId IdType="pubmed">28432138</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauba E, Sui S, Tian J, Driskill C, Jia K, Yu C, et al. Modulation of OSCP mitigates mitochondrial and synaptic deficits in a mouse model of Alzheimer&#x2019;s pathology. Neurobiol Aging. 2021;98:3&#x2013;77. doi: 10.1016/j.neurobiolaging.2020.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.09.018</ArticleId><ArticleId IdType="pmc">PMC7923248</ArticleId><ArticleId IdType="pubmed">33254080</ArticleId></ArticleIdList></Reference><Reference><Citation>Handran SD, Werth JL, DeVivo DC, Rothman SM. Mitochondrial morphology and intracellular calcium homeostasis in cytochrome oxidase-deficient human fibroblasts. Neurobiol Dis. 1997;3:87&#x2013;298. doi: 10.1006/nbdi.1996.0125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.1996.0125</ArticleId><ArticleId IdType="pubmed">9173926</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray NE, Quinn JF. Alterations in mitochondrial number and function in Alzheimer&#x2019;s disease fibroblasts. Metab Brain Dis. 2015;30:275&#x2013;1278. doi: 10.1007/s11011-015-9667-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-015-9667-z</ArticleId><ArticleId IdType="pmc">PMC4800977</ArticleId><ArticleId IdType="pubmed">25862550</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n-Maestro P, Gargini R, Garc&#xed;a E, Perry G, Avila J, Garc&#xed;a-Escudero V. Slower dynamics and aged mitochondria in sporadic Alzheimer&#x2019;s disease. Oxid Med Cell Longev. 2017;2017:14. doi: 10.1155/2017/9302761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/9302761</ArticleId><ArticleId IdType="pmc">PMC5672147</ArticleId><ArticleId IdType="pubmed">29201274</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi AU, Saw NL, Shamloo M, Mochly-Rosen D. Drp1:Fis1 interaction mediates mitochondrial dysfunction bioenergetic failure and cognitive decline in Alzheimer&#x2019;s disease. Oncotarget. 2017;9(5):6128&#x2013;6143. doi: 10.18632/oncotarget.23640.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.23640</ArticleId><ArticleId IdType="pmc">PMC5814200</ArticleId><ArticleId IdType="pubmed">29464060</ArticleId></ArticleIdList></Reference><Reference><Citation>MacVicar T, Langer T. OPA1 processing in cell death and disease&#x2014;the long and short of it. J Cell Sci. 2016;129:297&#x2013;2306.</Citation><ArticleIdList><ArticleId IdType="pubmed">27189080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wai T, Langer T. Mitochondrial dynamics and metabolic regulation. Trends Endocrinol Metabolism. 2016;27:05&#x2013;117. doi: 10.1016/j.tem.2015.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2015.12.001</ArticleId><ArticleId IdType="pubmed">26754340</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n-Maestro P, Gargini R, Sproul AA, Garc&#xed;a E, Ant&#xf3;n LC, Noggle S, et al. Mitophagy failure in fibroblasts and iPSC-derived neurons of Alzheimer&#x2019;s disease-associated presenilin 1 mutation. Front Mol Neurosci. 2017;10:91. doi: 10.3389/fnmol.2017.00291.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00291</ArticleId><ArticleId IdType="pmc">PMC5603661</ArticleId><ArticleId IdType="pubmed">28959184</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramamoorthy M, Sykora P, Scheibye-Knudsen M, Dunn C, Kasmer C, Zhang Y, et al. Sporadic Alzheimer disease fibroblasts display an oxidative stress phenotype. Free Radic Biolb Med. 2012;53:371&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4617209</ArticleId><ArticleId IdType="pubmed">22885031</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannuzzi F, Frisardi V, Annunziato L, Matrone C. Might fibroblasts from patients with Alzheimer&#x2019;s disease reflect the brain pathology? a focus on the increased phosphorylation of amyloid precursor protein Tyr682 residue. Brain Sci. 2021;11:03. doi: 10.3390/brainsci11010103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11010103</ArticleId><ArticleId IdType="pmc">PMC7828817</ArticleId><ArticleId IdType="pubmed">33466666</ArticleId></ArticleIdList></Reference><Reference><Citation>Drabik K, Mali&#x144;ska D, Piecyk K, D&#x119;bska-Vielhaber G, Vielhaber S, Duszy&#x144;ski J, et al. Effect of chronic stress present in fibroblasts derived from patients with a sporadic form of AD on mitochondrial function and mitochondrial turnover. Antioxidants. 2021;10:38. doi: 10.3390/antiox10060938.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10060938</ArticleId><ArticleId IdType="pmc">PMC8229029</ArticleId><ArticleId IdType="pubmed">34200581</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson C, Goldman JE. Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci U S A. 1986;83:758&#x2013;2762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323380</ArticleId><ArticleId IdType="pubmed">3458236</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf6;nnies E, Trushina E. Oxidative stress synaptic dysfunction and Alzheimer&#x2019;s disease. J Alzheimers Dis. 2017;57:105&#x2013;1121. doi: 10.3233/JAD-161088.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-161088</ArticleId><ArticleId IdType="pmc">PMC5409043</ArticleId><ArticleId IdType="pubmed">28059794</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchi C, Fiorillo C, Sorbi S, Latorraca S, Nacmias B, Bagnoli S, et al. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer&#x2019;s patients. Free Radical Bio Med. 2002;33:372&#x2013;1379. doi: 10.1016/S0891-5849(02)01049-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0891-5849(02)01049-3</ArticleId><ArticleId IdType="pubmed">12419469</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature. 2005;434:52&#x2013;658. doi: 10.1038/nature03317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03317</ArticleId><ArticleId IdType="pubmed">15800626</ArticleId></ArticleIdList></Reference><Reference><Citation>Du H, Yan SS. Mitochondrial permeability transition pore in Alzheimer&#x2019;s disease: cyclophilin D and amyloid beta. Biochim Biophys Acta. 2010;1802:98&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280723</ArticleId><ArticleId IdType="pubmed">19616093</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrosillo G, Ruggiero FM, Pistolese M, Paradies G. Ca2+-induced reactive oxygen species production promotes cytochrome c release from rat liver mitochondria via mitochondrial permeability transition (MPT)-dependent and MPT-independent mechanisms -role of cardiolipin. J Biol Chem. 2004;279:3103&#x2013;53108. doi: 10.1074/jbc.M407500200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M407500200</ArticleId><ArticleId IdType="pubmed">15475362</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos RX, Correia SC, Zhu X, Smith MA, Moreira PI, Castellani RJ, et al. Mitochondrial DNA oxidative damage and repair in aging and Alzheimer&#x2019;s disease. Antioxid Redox Sign. 2013;18:444&#x2013;2457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3671662</ArticleId><ArticleId IdType="pubmed">23216311</ArticleId></ArticleIdList></Reference><Reference><Citation>Monte SM, de la Luong T, Neely TR, Robinson D, Wands JR. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer&#x2019;s disease. Lab Invest. 2000;80:323&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="pubmed">10950123</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer&#x2019;s disease. J Neurochem. 2005;93:53&#x2013;962. doi: 10.1111/j.1471-4159.2004.02995.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02995.x</ArticleId><ArticleId IdType="pubmed">15857398</ArticleId></ArticleIdList></Reference><Reference><Citation>Grazina M, Silva F, Santana I, Pratas J, Santiago B, Oliveira M, et al. Mitochondrial DNA variants in a Portuguese population of patients with Alzheimer&#x2019;s disease. Eur Neurol. 2005;53:21&#x2013;124. doi: 10.1159/000085555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000085555</ArticleId><ArticleId IdType="pubmed">15860916</ArticleId></ArticleIdList></Reference><Reference><Citation>Curti D, Rognoni F, Gasparini L, Cattaneo A, Paolillo M, Racchi M, et al. Oxidative metabolism in cultured fibroblasts derived from sporadic Alzheimer&#x2019;s disease (AD) patients. Neurosci Lett. 1997;236:3&#x2013;16. doi: 10.1016/S0304-3940(97)00741-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(97)00741-6</ArticleId><ArticleId IdType="pubmed">9404940</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell SM, Marco MD, Barnes K, Shaw PJ, Ferraiuolo L, Blackburn DJ, et al. Deficits in mitochondrial spare respiratory capacity contribute to the neuropsychological changes of Alzheimer&#x2019;s disease. J Person Med. 2020;10:2. doi: 10.3390/jpm10020032.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm10020032</ArticleId><ArticleId IdType="pmc">PMC7354560</ArticleId><ArticleId IdType="pubmed">32365522</ArticleId></ArticleIdList></Reference><Reference><Citation>Drabik K, Mali&#x144;ska D, Piecyk K, D&#x119;bska-Vielhaber G, Vielhaber S, Duszy&#x144;ski J, et al. Effect of chronic stress present in fibroblasts derived from patients with a sporadic form of AD on mitochondrial function and mitochondrial turnover. Antioxidants (Basel) 2021;10(6):938. doi: 10.3390/antiox10060938.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10060938</ArticleId><ArticleId IdType="pmc">PMC8229029</ArticleId><ArticleId IdType="pubmed">34200581</ArticleId></ArticleIdList></Reference><Reference><Citation>Galla L, Redolfi N, Pozzan T, Pizzo P, Greotti E. Intracellular calcium dysregulation by the Alzheimer&#x2019;s disease-linked protein Presenilin 2. Int J Mol Sci. 2020;21:70. doi: 10.3390/ijms21030770.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21030770</ArticleId><ArticleId IdType="pmc">PMC7037278</ArticleId><ArticleId IdType="pubmed">31991578</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonntag KC, Ryu WI, Amirault KM, Healy RA, Siegel AJ, McPhie DL, et al. Late-onset Alzheimer&#x2019;s disease is associated with inherent changes in bioenergetics profiles. Sci Rep. 2017;7:4038. doi: 10.1038/s41598-017-04416-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04416-y</ArticleId><ArticleId IdType="pmc">PMC5656579</ArticleId><ArticleId IdType="pubmed">29070876</ArticleId></ArticleIdList></Reference><Reference><Citation>Bose A, Beal MF. Mitochondrial dysfunction in Parkinson&#x2019;s disease. J Neurochem. 2016;139:16&#x2013;231. doi: 10.1111/jnc.13731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13731</ArticleId><ArticleId IdType="pubmed">27546335</ArticleId></ArticleIdList></Reference><Reference><Citation>Teves JMY, Bhargava V, Kirwan KR, Corenblum MJ, Justiniano R, Wondrak GT, et al. Parkinson&#x2019;s disease skin fibroblasts display signature alterations in growth redox homeostasis mitochondrial function and autophagy. Front Neurosci. 2018;11:37. doi: 10.3389/fnins.2017.00737.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00737</ArticleId><ArticleId IdType="pmc">PMC5770791</ArticleId><ArticleId IdType="pubmed">29379409</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakovic A, Gr&#xfc;newald A, Kottwitz J, Br&#xfc;ggemann N, Pramstaller PP, Lohmann K, et al. Mutations in PINK1 and Parkin impair ubiquitination of mitofusins in human fibroblasts. PLoS ONE. 2011;6:e16746. doi: 10.1371/journal.pone.0016746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0016746</ArticleId><ArticleId IdType="pmc">PMC3050809</ArticleId><ArticleId IdType="pubmed">21408142</ArticleId></ArticleIdList></Reference><Reference><Citation>Palikaras K, Lionaki E, Tavernarakis N. Mechanisms of mitophagy in cellular homeostasis physiology and pathology. Nat Cell Biol. 2018;20:013&#x2013;1022. doi: 10.1038/s41556-018-0176-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-018-0176-2</ArticleId><ArticleId IdType="pubmed">30154567</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincow ES, Merrihew G, Thomas RE, Shulman NJ, Beyer RP, MacCoss MJ, et al. The PINK1&#x2013;Parkin pathway promotes both mitophagy and selective respiratory chain turnover in vivo. Proc Natl Acad Sci U S A. 2013;110:400&#x2013;6405. doi: 10.1073/pnas.1221132110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1221132110</ArticleId><ArticleId IdType="pmc">PMC3631677</ArticleId><ArticleId IdType="pubmed">23509287</ArticleId></ArticleIdList></Reference><Reference><Citation>Grenier K, McLelland GL, Fon EA. Parkin- and PINK1-dependent mitophagy in neurons: will the real pathway please stand up? Front Neurol. 2013;4:00. doi: 10.3389/fneur.2013.00100.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2013.00100</ArticleId><ArticleId IdType="pmc">PMC3715719</ArticleId><ArticleId IdType="pubmed">23882257</ArticleId></ArticleIdList></Reference><Reference><Citation>Vives-Bauza C, Zhou C, Huang Y, Cui M, de Vries RLA, Kim J, et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci USA. 2010;107:78&#x2013;383. doi: 10.1073/pnas.0911187107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0911187107</ArticleId><ArticleId IdType="pmc">PMC2806779</ArticleId><ArticleId IdType="pubmed">19966284</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortiboys H, Thomas KJ, Koopman WJH, Klaffke S, Abou-Sleiman P, Olpin S, et al. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann Neurol. 2008;64:55&#x2013;565. doi: 10.1002/ana.21492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21492</ArticleId><ArticleId IdType="pmc">PMC2613566</ArticleId><ArticleId IdType="pubmed">19067348</ArticleId></ArticleIdList></Reference><Reference><Citation>Anichtchik O, Diekmann H, Fleming A, Roach A, Goldsmith P, Rubinsztein DC. Loss of PINK1 function affects development and results in neurodegeneration in zebrafish. J Neurosci. 2008;28:199&#x2013;8207. doi: 10.1523/JNEUROSCI.0979-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0979-08.2008</ArticleId><ArticleId IdType="pmc">PMC6670558</ArticleId><ArticleId IdType="pubmed">18701682</ArticleId></ArticleIdList></Reference><Reference><Citation>Exner N, Treske B, Paquet D, Holmstr&#xf6;m K, Schiesling C, Gispert S, et al. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by Parkin. J Neurosci. 2007;27:2413&#x2013;12418. doi: 10.1523/JNEUROSCI.0719-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0719-07.2007</ArticleId><ArticleId IdType="pmc">PMC6673250</ArticleId><ArticleId IdType="pubmed">17989306</ArticleId></ArticleIdList></Reference><Reference><Citation>Gegg ME, Cooper JM, Chau KY, Rojo M, Schapira AHV, Taanman JW. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum Mol Genet. 2010;19:861&#x2013;4870. doi: 10.1093/hmg/ddq419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq419</ArticleId><ArticleId IdType="pmc">PMC3583518</ArticleId><ArticleId IdType="pubmed">20871098</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakovic A, Gr&#xfc;newald A, Seibler P, Ramirez A, Kock N, Orolicki S, et al. Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Hum Mol Genet. 2010;19:124&#x2013;3137. doi: 10.1093/hmg/ddq215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq215</ArticleId><ArticleId IdType="pubmed">20508036</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakhine-Diop SMS, Niso-Santano M, Rodr&#xed;guez-Arribas M, G&#xf3;mez-S&#xe1;nchez R, Mart&#xed;nez-Chac&#xf3;n G, Uribe-Carretero E, et al. Impaired mitophagy and protein acetylation levels in fibroblasts from Parkinson&#x2019;s disease patients. Mol Neurobiol. 2019;56:466&#x2013;2481. doi: 10.1007/s12035-018-1206-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1206-6</ArticleId><ArticleId IdType="pubmed">30032424</ArticleId></ArticleIdList></Reference><Reference><Citation>Mytilineou C, Werner P, Molinari S, Rocco A, Cohen G, Yahr MD. Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson&#x2019;s disease. J Neural Transm. 1994;8:23&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">7748465</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker WD, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic parkinson&#x2019;s disease. Ann Neurol. 2013;26:19&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">2557792</ArticleId></ArticleIdList></Reference><Reference><Citation>Smigrodzki R, Parks J, Parker WD. High frequency of mitochondrial complex I mutations in Parkinson&#x2019;s disease and aging. Neurobiol Aging. 2004;25:273&#x2013;1281. doi: 10.1016/j.neurobiolaging.2004.02.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.02.020</ArticleId><ArticleId IdType="pubmed">15465623</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet. 2006;38:18&#x2013;520. doi: 10.1038/ng1778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1778</ArticleId><ArticleId IdType="pubmed">16604072</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Shachar D, Zuk R, Gazawi H, Ljubuncic P. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem Pharmacol. 2004;67:965&#x2013;1974. doi: 10.1016/j.bcp.2004.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2004.02.015</ArticleId><ArticleId IdType="pubmed">15130772</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker WD, Parks JK, Swerdlow RH. Complex I deficiency in Parkinson&#x2019;s disease frontal cortex. Brain Res. 2008;1189:15&#x2013;218. doi: 10.1016/j.brainres.2007.10.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.10.061</ArticleId><ArticleId IdType="pmc">PMC2295283</ArticleId><ArticleId IdType="pubmed">18061150</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopman WJH, Visch HJ, Verkaart S, Van Heuvel LWPJ, den Smeitink JAM, Willems PHGM. Mitochondrial network complexity and pathological decrease in complex I activity are tightly correlated in isolated human complex I deficiency. Am J Physiol. 2005;289:C881&#x2013;C890. doi: 10.1152/ajpcell.00104.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00104.2005</ArticleId><ArticleId IdType="pubmed">15901599</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Perez E, Dalf&#xf3; E, Barrachina M. Abnormal levels of prohibitin and ATP synthase in the substantia nigra and frontal cortex in Parkinson&#x2019;s disease. Neurosci Lett. 2007;415:05&#x2013;209. doi: 10.1016/j.neulet.2007.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2007.01.026</ArticleId><ArticleId IdType="pubmed">17284347</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of &#x3b1;-synuclein impair complex i in human dopaminergic neuronal cultures and parkinson disease brain. J Biol Chem. 2008;283:089&#x2013;9100. doi: 10.1074/jbc.M710012200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M710012200</ArticleId><ArticleId IdType="pmc">PMC2431021</ArticleId><ArticleId IdType="pubmed">18245082</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinta SJ, Mallajosyula JK, Rane A, Andersen JK. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett. 2010;486:35&#x2013;239. doi: 10.1016/j.neulet.2010.09.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2010.09.061</ArticleId><ArticleId IdType="pmc">PMC2967673</ArticleId><ArticleId IdType="pubmed">20887775</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak SK, Tewari D, Tetrud JW, Langston JW, Sch&#xfc;le B. Mitochondrial dysfunction in skin fibroblasts from a Parkinson&#x2019;s disease patient with an alpha-synuclein triplication. J Park Dis. 2011;1:75&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">23934919</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanellati MC, Monti V, Barzaghi C, Reale C, Nardocci N, Albanese A, et al. Mitochondrial dysfunction in Parkinson disease: evidence in mutant PARK2 fibroblasts. Front Genetics. 2015;6:8. doi: 10.3389/fgene.2015.00078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2015.00078</ArticleId><ArticleId IdType="pmc">PMC4356157</ArticleId><ArticleId IdType="pubmed">25815004</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xfc;newald A, Voges L, Rakovic A, Kasten M, Vandebona H, Hemmelmann C, et al. Mutant Parkin impairs mitochondrial function and morphology in human fibroblasts. PLoS ONE. 2010;5:e12962. doi: 10.1371/journal.pone.0012962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0012962</ArticleId><ArticleId IdType="pmc">PMC2946349</ArticleId><ArticleId IdType="pubmed">20885945</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#x119;drak P, Mozolewski P, W&#x119;grzyn G, Wi&#x119;ckowski MR. Mitochondrial alterations accompanied by oxidative stress conditions in skin fibroblasts of Huntington&#x2019;s disease patients. Metab Brain Dis. 2018;33:005&#x2013;2017. doi: 10.1007/s11011-018-0308-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-018-0308-1</ArticleId><ArticleId IdType="pmc">PMC6244791</ArticleId><ArticleId IdType="pubmed">30120672</ArticleId></ArticleIdList></Reference><Reference><Citation>Squitieri F, Falleni A, Cannella M, Orobello S, Fulceri F, Lenzi P, et al. Abnormal morphology of peripheral cell tissues from patients with Huntington disease. J Neural Transm. 2009;117:7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19834779</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W, Chen J, Petrilli A, Liot G, Klinglmayr E, Zhou Y, et al. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat Med. 2011;17:77&#x2013;382. doi: 10.1038/nm.2313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2313</ArticleId><ArticleId IdType="pmc">PMC3051025</ArticleId><ArticleId IdType="pubmed">21336284</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenas J, Campos Y, Ribacoba R, Mart&#xed;n MA, Rubio JC, Ablanedo P, et al. Complex I defect in muscle from patients with Huntington&#x2019;s disease: complex I defect in HD. Ann Neurol. 1998;43:97&#x2013;400. doi: 10.1002/ana.410430321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410430321</ArticleId><ArticleId IdType="pubmed">9506560</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#x119;drak P, Krygier M, To&#x144;ska K, Drozd M, Kaliszewska M, Bartnik E, et al. Mitochondrial DNA levels in Huntington disease leukocytes and dermal fibroblasts. Metab Brain Dis. 2017;32:237&#x2013;1247. doi: 10.1007/s11011-017-0026-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-017-0026-0</ArticleId><ArticleId IdType="pmc">PMC5504138</ArticleId><ArticleId IdType="pubmed">28508341</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung CLK, Maiuri T, Bowie LE, Gotesman R, Son S, Falcone M, et al. A patient-derived cellular model for Huntington&#x2019;s disease reveals phenotypes at clinically relevant CAG lengths. Mol Biol Cell. 2018;29:809&#x2013;2820. doi: 10.1091/mbc.E18-09-0590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E18-09-0590</ArticleId><ArticleId IdType="pmc">PMC6249865</ArticleId><ArticleId IdType="pubmed">30256717</ArticleId></ArticleIdList></Reference><Reference><Citation>Onesto E, Colombrita C, Gumina V, Borghi MO, Dusi S, Doretti A, et al. Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts. Acta Neuropathologica Commun. 2016;4:7. doi: 10.1186/s40478-016-0316-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0316-5</ArticleId><ArticleId IdType="pmc">PMC4858818</ArticleId><ArticleId IdType="pubmed">27151080</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin EC, Bannwarth S, Lespinasse F, Ortega-Vila B, Fragaki K, Itoh K, et al. Loss of MICOS complex integrity and mitochondrial damage but not TDP-43 mitochondrial localisation are likely associated with severity of CHCHD10-related diseases. Neurobiol Dis. 2018;119:59&#x2013;171. doi: 10.1016/j.nbd.2018.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.07.027</ArticleId><ArticleId IdType="pmc">PMC7015038</ArticleId><ArticleId IdType="pubmed">30092269</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzardini M, Mangolini A, Lupi M, Ubezio P, Bendotti C, Cantoni L. Low levels of ALS-linked Cu/Zn superoxide dismutase increase the production of reactive oxygen species and cause mitochondrial damage and death in motor neuron-like cells. J Neurol Sci. 2005;232:5&#x2013;103. doi: 10.1016/j.jns.2005.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2005.02.004</ArticleId><ArticleId IdType="pubmed">15850589</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen SP, Duffy LM, Shaw PJ, Grierson AJ. Altered age-related changes in bioenergetic properties and mitochondrial morphology in fibroblasts from sporadic amyotrophic lateral sclerosis patients. Neurobiol Aging. 2015;36:893&#x2013;2903. doi: 10.1016/j.neurobiolaging.2015.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.07.013</ArticleId><ArticleId IdType="pubmed">26344876</ArticleId></ArticleIdList></Reference><Reference><Citation>Debska-Vielhaber G, Miller I, Peeva V, Zuschratter W, Walczak J, Schreiber S, et al. Impairment of mitochondrial oxidative phosphorylation in skin fibroblasts of SALS and FALS patients is rescued by in vitro treatment with ROS scavengers. Exp Neurol. 2021;339:13620. doi: 10.1016/j.expneurol.2021.113620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2021.113620</ArticleId><ArticleId IdType="pubmed">33497646</ArticleId></ArticleIdList></Reference><Reference><Citation>Szelechowski M, Amoedo N, Obre E, L&#xe9;ger C, Allard L, Bonneu M, et al. Metabolic reprogramming in amyotrophic lateral sclerosis. Sci Rep. 2018;8:953. doi: 10.1038/s41598-018-22318-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-22318-5</ArticleId><ArticleId IdType="pmc">PMC5834494</ArticleId><ArticleId IdType="pubmed">29500423</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen GA, Wanders RJA, J&#xf6;bsis GJ, Bolhuis PA, de Jong JM. Evidence against increased oxidative stress in fibroblasts from patients with non-superoxide-dismutase-1 mutant familial amyotrophic lateral sclerosis. J Neurol Sci. 1996;139:1&#x2013;94. doi: 10.1016/0022-510X(96)00070-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(96)00070-6</ArticleId><ArticleId IdType="pubmed">8899665</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre T, Bosch L, Van D, Goetschalckx K, Tilkin P, Mathijis G, et al. Increased sensitivity of fibroblasts from amyotrophic lateral sclerosis patients to oxidative stress. Ann Neurol. 1998;43:52&#x2013;457. doi: 10.1002/ana.410430407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410430407</ArticleId><ArticleId IdType="pubmed">9546325</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr&#xec; MT, Valle C, Bozzo F, Cozzolino M. Oxidative stress and mitochondrial damage: importance in non-SOD1 ALS. Front Cell Neurosci. 2015;9:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4330888</ArticleId><ArticleId IdType="pubmed">25741238</ArticleId></ArticleIdList></Reference><Reference><Citation>Siebel A, Cubillos-Rojas M, Santos RC, Schneider T, Bonan CD, Bartrons R, et al. Contribution of S6K1/MAPK signaling pathways in the response to oxidative stress: activation of RSK and MSK by hydrogen peroxide. PLoS ONE. 2013;8:e75523. doi: 10.1371/journal.pone.0075523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0075523</ArticleId><ArticleId IdType="pmc">PMC3776792</ArticleId><ArticleId IdType="pubmed">24058693</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>